| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bionano Genomics, Inc.$1.14
-0.01 (-0.9%)
F 5Pipeline Score Diagnostics · Commercial
Market Cap
14.23 M
EPS
-5.08
P/E Ratio
-
Value Trade
327.46 K
SEC Financials
Q1 2026Dilution Risk
Revenue
6.69 M
R&D Expenses
3.14 M
Operating CF
-5.72 M
Total Assets
64.80 M
Total Liabilities
27.34 M
Equity
37.46 M
D/E Ratio
12,345
4.2 %
Week
-1.59 %
1 Month
7.83 %
3 Month
-16.78 %
6 Month
-99.96 %
5 Year
-99.98 %
All Time
Cash Data
Cash Position
14.41 M
Monthly Burn
1.91 M
Runway
6.4 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
21.50 K
52 Week Range
1.06 - 5.50
% held by Insiders
6.02 %
% held by Institutions
12.86 %
Enterprise Value
6.57 M
Total Shares
11.10 M
Short %
10.13 %
Float Shares
11.08 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F5
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 5%
Micro Cap (rank 861 of 905)
Percentile RankBionano Genomics, Inc. has significant pipeline risk (5/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BNGO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
BNGO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BNGO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BNGO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BNGO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BNGO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BNGOBionano Announces Hiring of Chief Scientific Officer
Bionano Genomics has appointed Dr. Alex Hastie as Chief Scientific Officer, effective July 20, 2026. Dr. Hastie, a key figure in the company's technology development, will lead the scientific strategy and innovation roadmap. His return is positively received by the scientific community, who anticipate advancements in optical genome mapping and clinical applications.
Read more →BNGOBionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption
Bionano Genomics reported a 67% year-over-year increase in studies featuring optical genome mapping (OGM) at the 2026 ESHG conference. The growth reflects a broader global adoption of OGM, with contributions from 17 countries. Key research themes included rare genetic disorders and hematologic malignancies, highlighting OGM's potential in advancing cytogenomics.
Read more →BNGOBionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
Bionano Genomics announced the publication of 13 studies in 2026 highlighting the effectiveness of optical genome mapping (OGM) in reproductive health and prenatal genetic disorders. These studies, which involved 730 samples, demonstrated OGM's superior ability to detect and characterize structural variants compared to conventional methods like karyotyping. Key findings indicate that OGM outperformed traditional diagnostics in numerous cases, identifying previously undetectable genetic causes of infertility, miscarriages, and prenatal conditions. The breadth of research showcases OGM's significant role in advancing clinical genetic practices.
Read more →BNGOBionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
Bionano Genomics has announced the complete retirement of its Senior Secured Convertible Debentures, originally valued at $20 million. This move, funded by cash on hand, eliminates all secured debt obligations, enhancing the company's financial flexibility. The chairman emphasized that this milestone allows Bionano to concentrate on growing its optical genome mapping business and executing its commercial strategy.
Read more →BNGOBionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
Bionano Genomics announced a peer-reviewed study showing that optical genome mapping (OGM) significantly outperforms conventional cytogenetic methods in detecting genomic abnormalities in T-cell acute lymphoblastic leukemia (T-ALL). The study, conducted with 91 subjects, found a detection rate of 97.8% for OGM compared to 55% for traditional methods. This research highlights OGM's potential to enhance understanding and treatment of this aggressive cancer.
Read more →BNGOBionano Reports First Quarter 2026 Results and Provides a Business Update Conference call today
Bionano Genomics reported its financial results for Q1 2026, revealing a 4% increase in total revenue, reaching $6.7 million. The company experienced strong growth in consumables revenue, which saw a 20% rise. Significant advancements were noted with newly implemented CPT codes enhancing reimbursement rates for OGM services. The company is also closing in on the retirement of secured convertible debt, which will bolster its financial stability for future investments.
Read more →BNGOBionano Announces Leadership Transition
Bionano Genomics has appointed Al Luderer as interim president and CEO, effective May 5, 2026. He succeeds Erik Holmlin, who remains as an advisor. Luderer, with over 30 years in biotechnology, aims to ensure a smooth transition and continue the company's growth. The board expresses confidence in his leadership during this period.
Read more →BNGOBionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025
Bionano Genomics reported a 56% increase in publications related to optical genome mapping (OGM) for rare diseases in Q1 2026 compared to Q1 2025. The findings reveal that OGM significantly enhances the identification and characterization of structural variants, often missed by traditional methods. A total of 28 publications were analyzed, reflecting a substantial growth in the use of OGM across various global institutions. The studies collectively emphasized OGM's role in resolving previously unexplained rare disease cases and its potential as a gold standard technique for genomic analysis.
Read more →BNGOBionano to Report First Quarter 2026 Financial Results and Host a Conference Call Webcast on May 13, 2026
Bionano Genomics, Inc. has announced a conference call and webcast scheduled for May 13, 2026, at 4:30 p.m. ET to discuss its first quarter 2026 financial results. The event will also cover recent corporate developments. Participants can access the live webcast through the company's investor relations page.
Read more →BNGOBionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma
Bionano Genomics announced a study showing that optical genome mapping (OGM) outperforms traditional methods in analyzing multiple myeloma. The multicenter research, published in the American Journal of Hematology, demonstrated OGM's higher success rates in detecting chromosomal abnormalities and its ability to identify additional pathogenic findings. The study supports the integration of OGM into standard laboratory workflows for better genomic profiling.
Read more →BNGOBionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026
Bionano Genomics reported its financial results for Q4 and the full year 2025, highlighting significant growth in optical genome mapping utilization. The company anticipates continued momentum into 2026, bolstered by increased payment rates for OGM services and strong engagement from the global OGM community. CEO Erik Holmlin expressed optimism about the future of OGM in clinical applications.
Read more →BNGOBionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Bionano Genomics announced a significant increase in the studies presented at the 2026 ACMG Annual Meeting, where twelve studies focused on the application of optical genome mapping (OGM) in detecting structural variants. This marks a two-fold increase compared to previous years, illustrating the technique's growing relevance in cancer genomics and genetic disorders. Attendees engaged in workshops to learn about OGM applications from experts, while Baylor Genetics launched a new service to enhance research accessibility to OGM data. Despite the positives, the announcement also contains forward-looking statements that come with uncertainties affecting future performance.
Read more →BNGOBionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026
Bionano Genomics, Inc. has announced a conference call and live webcast scheduled for March 23, 2026, at 4:30 p.m. Eastern Time. The purpose of this event is to report the financial results for the fourth quarter and full year of 2025, as well as to highlight recent corporate progress. Participants can access the live webcast through the Bionano Investors page, and a replay will be available for 30 days.
Read more →BNGOBionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale
Bionano Genomics concluded Symposium 2026, highlighting advancements in optical genome mapping (OGM) and its applications in cytogenetics and molecular pathology. Over 1,250 attendees participated, with presentations from leading laboratories discussing automation and scalability of OGM. Key speakers emphasized the transformative potential of OGM in research and clinical settings, showcasing innovations that enhance genome analysis.
Read more →BNGO10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM’s Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders
Bionano Genomics showcased the utility of optical genome mapping (OGM) in addressing complex constitutional genetic disorders during Day 3 of its 2026 Symposium. Presentations from global experts illustrated OGM's ability to detect previously undetectable genetic variants and structural rearrangements, emphasizing its transformative role in genetic research. The event attracted over 1,200 participants, reflecting a growing interest in OGM applications.
Read more →BNGO11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding Impact of Optical Genome Mapping Across Oncology and Cell & Gene Therapy
Bionano Genomics showcased advancements in Optical Genome Mapping (OGM) at Symposium 2026, emphasizing its role in oncology and cell therapy. Presentations highlighted OGM's ability to detect structural variants in cancers, including rare types. The event saw significant participation, indicating growing interest in OGM's applications in genomic research and therapeutic innovation.
Read more →BNGO9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies
Bionano Genomics hosted Day 1 of the Symposium 2026, focusing on Optical Genome Mapping (OGM) advancements in hematologic malignancies. Experts presented data showcasing OGM's capabilities in enhancing genomic analysis and its integration with traditional methods. The event attracted over 1000 attendees globally, emphasizing OGM's growing importance in cancer research.
Read more →BNGOBionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping
Bionano Genomics has announced the Bionano Symposium 2026, a virtual event showcasing advancements in optical genome mapping (OGM). Scheduled for February 23-26, 2026, the symposium will feature presentations from over 30 researchers worldwide, focusing on applications in oncology, genetic disorders, and more. The event aims to foster collaboration and innovation within the OGM community.
Read more →BNGOBionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies
Bionano Genomics announced a peer-reviewed study demonstrating the effectiveness of optical genome mapping (OGM) in detecting genomic alterations from gene editing technologies. The research indicates that OGM can serve as a crucial quality control tool in ensuring genome integrity during the development of gene editing therapies. The study highlights OGM's superiority over traditional methods in identifying complex structural variants.
Read more →BNGOBionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results
Bionano Genomics reported preliminary financial results for Q4 and the full year of 2025, highlighting a transformation towards routine users of their optical genome mapping (OGM) solutions. The company noted important developments, including a new CPT code for OGM in genetic disorders and improving financial performance with reduced cash burn. Despite these positives, the financial results are preliminary and subject to change, bringing inherent uncertainty about their implications for future performance.
Read more →BNGOBionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025
Bionano Genomics showcased its optical genome mapping (OGM) technology at the AMP Annual Meeting, emphasizing its superior ability to detect structural variants compared to traditional methods. Thirteen studies presented at the conference demonstrated OGM's expanding applications in inherited diseases, reproductive disorders, and cancers. The company aims to make comprehensive structural variant analysis routine in laboratories.
Read more →BNGOBionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress
Bionano Genomics, Inc. reported its financial results for the third quarter of 2025, highlighting a 21% increase in total revenue compared to the same period in 2024. The company has implemented a strategic shift towards consumables and software utilization among routine users, contributing to improved margins and disciplined expense management. Notably, the gross margin reached 46%, a significant improvement from the prior year's negative gross margin. Additionally, Bionano completed a public offering that raised $10 million, aiming to bolster its growth trajectory and expand its operations.
Read more →BNGOBionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia
Bionano Genomics announced a study demonstrating that optical genome mapping (OGM) can effectively address limitations of targeted RNA-sequencing in detecting gene rearrangements in acute leukemia. The research shows that OGM identifies a higher proportion of clinically significant structural variants compared to RNA-seq. The combination of both techniques is recommended for the most comprehensive results in acute leukemia cases.
Read more →BNGOBionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025
Bionano Genomics, Inc. will host a conference call and webcast on November 13, 2025, to discuss its third quarter 2025 financial results. The event will take place at 4:30 p.m. Eastern Time, and a replay will be available for 30 days. This call aims to inform investors about the company's recent progress.
Read more →BNGOBionano Highlights Global Momentum Behind OGM at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) Meeting
Bionano Genomics showcased the advancements of optical genome mapping (OGM) at the ASHG 2025 conference, highlighting its effectiveness in detecting structural variants linked to various genetic disorders. Nine studies presented at the event underscored OGM's potential to enhance understanding of complex genetic conditions. The company remains committed to advancing OGM technology in the scientific community.
Read more →BNGOBionano to Participate in the H.C. Wainwright @ Home Event
Bionano Genomics, Inc. announced that its CEO, Erik Holmlin, will participate in the H.C. Wainwright @ Home Event on October 15, 2025. This event is an opportunity for the company to showcase its advancements in genome analysis solutions. A recording of the session will be available for 90 days post-event on the Bionano website.
Read more →BNGOBionano Genomics, Inc. Announces Closing of $10 Million Public Offering
Bionano Genomics, Inc. has successfully closed a public offering, generating approximately $10 million. The offering included 5 million shares and warrants, with potential additional proceeds of $20 million if the warrants are exercised. The funds will be utilized for working capital and general corporate purposes, although there are risks regarding the exercise of the warrants and reimbursement for tests.
Read more →BNGOBionano Genomics, Inc. Announces Pricing of $10 Million Public Offering
Bionano Genomics, Inc. has announced a public offering of 5 million shares priced at $2.00 each, aiming to raise approximately $10 million. The offering includes Series E and F warrants, which could generate an additional $20 million if exercised. The proceeds will be used for working capital and corporate purposes, with the closing expected on September 17, 2025.
Read more →BNGOMultiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular Biology
Bionano Genomics announced the publication of a dedicated issue of 'Methods in Molecular Biology' featuring studies on chromoanagenesis, emphasizing the utility of optical genome mapping (OGM) in cancer research. The studies demonstrate OGM's ability to detect complex genomic rearrangements associated with poor prognosis and treatment resistance. The findings suggest OGM could significantly impact disease management strategies.
Read more →BNGOCMS Posts Preliminary Payment Determination for New Category I CPT Code Covering Use of OGM for Constitutional Genetic Disorders
Bionano Laboratories announced that CMS has posted a preliminary payment determination for a new Category I CPT code for optical genome mapping (OGM) used in detecting constitutional genetic disorders. This code, effective January 1, 2026, will allow for higher reimbursement rates compared to traditional methods. The new code is expected to facilitate the adoption of OGM in clinical settings, enhancing its utility in genetic testing.
Read more →BNGOBionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Bionano Genomics, Inc. announced that its CEO, Erik Holmlin, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The company aims to enhance understanding of the genome through its innovative optical genome mapping solutions. A recording of the presentation will be available on their website for 30 days post-conference.
Read more →BNGOBionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress
Bionano Genomics reported strong financial results for Q2 2025, highlighting a gross margin above 50% and successful execution of its strategy aimed at routine users of optical genome mapping. The company anticipates continued growth in Q3 2025, supported by software upgrades and cost reduction efforts. CEO Erik Holmlin expressed confidence in the ongoing strategy's effectiveness.
Read more →BNGOBionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALL
Bionano Genomics announced a peer-reviewed study highlighting the utility of optical genome mapping (OGM) in identifying oncogenic structural variants in T-cell acute lymphoblastic leukemia (T-ALL) among infants and toddlers. Conducted by a team from leading French pediatric hematology centers, the study assessed 27 T-ALL cases and demonstrated how OGM revealed distinct genetic drivers and prognostic subgroups that were missed by conventional cytogenetics. The research showed comparable survival rates between infants and toddlers and older pediatric subjects, suggesting the potential of OGM as a complementary tool in stratifying patients by prognostic risk.
Read more →BNGOBionano to Present at the Canaccord Genuity 45th Annual Growth Conference
Bionano Genomics, Inc. has announced that its CEO, Erik Holmlin, will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025. The presentation will cover Bionano's genome analysis solutions and their transformative approach to understanding the genome. A recording of the session will be available on the Bionano website post-conference. The company emphasizes its focus on optical genome mapping and related diagnostic services.
Read more →BNGOBionano Announces Upgrades to its Software and Compute Platforms to Make Analysis of OGM, Microarray and NGS Data Easier, Faster and More Accurate
Bionano Genomics has announced significant upgrades to its genomic data analysis software, VIA 7.2 and Solve 3.8.3, aimed at improving the analysis of optical genome mapping (OGM), microarray, and next-generation sequencing data. The new software versions incorporate AI to enhance analysis speed and accuracy and are designed to automate variant calling and streamline interpretation processes. These advancements are expected to support both hematological malignancies and constitutional genetic disorders. The upgrades to Bionano's Stratys Compute server will enable the analysis of double the number of cancer samples per week, marking a considerable improvement in operational efficiency.
Read more →BNGOBionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on August 14, 2025
Bionano Genomics, Inc. has announced that it will report its financial results for the second quarter of 2025 on August 14, 2025. The company will host a conference call and live webcast at 4:30 p.m. ET, allowing participants to learn about recent corporate advancements. A replay of the event will be available on the company's investor relations website for at least 30 days after the conference.
Read more →BNGOBionano Recaps Momentum behind Optical Genome Mapping at the Biennial Meeting of the European Cytogenomics Association Held Recently in Leuven, Belgium
Bionano Genomics participated in the European Cytogenomics Conference in Leuven, Belgium, highlighting the growing momentum behind its Optical Genome Mapping (OGM) technology. The number of scientific presentations showcasing OGM's capabilities has increased, reflecting its rising adoption in clinical research. Dr. Erik Holmlin, Bionano's CEO, expressed optimism regarding OGM's future, emphasizing its potential to improve structural variant detection. However, the company also acknowledged uncertainties related to OGM's widespread acceptance in the market.
Read more →BNGOBionano Recaps Global Momentum Behind Optical Genome Mapping at the 2025 Annual Meeting of the European Society of Human Genetics Held Recently in Milan, Italy
Bionano Genomics participated in the ESHG conference in Milan, highlighting the advancements in optical genome mapping (OGM). The event showcased 21 studies from various countries, underlining OGM's effectiveness in detecting structural variants associated with genetic diseases. Dr. Erik Holmlin emphasized the increasing acknowledgment of OGM within the global scientific community, showcasing its potential for complex genetic issues. Bionano continues to aim for transformative advancements in genomic research through its OGM solutions.
Read more →BNGOBionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders
Bionano Laboratories announced the establishment of a second Category I CPT code by the American Medical Association for optical genome mapping (OGM). This new code will facilitate reimbursement for OGM tests related to constitutional genetic disorders and is expected to take effect on January 1, 2026. The approval highlights the increasing recognition of OGM's effectiveness over traditional methods for detecting structural variations in genomes. This follows a previous Category I code issued in 2024, further solidifying OGM's role in clinical diagnostics.
Read more →BNGOBionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
Bionano Genomics reported its financial results for Q1 2025, indicating a strategic focus on optical genome mapping (OGM) and software. While the company experienced a 26% decrease in total revenue compared to Q1 2024, there was a slight uptick in sales among routine users after adjustments. The financial performance was boosted by significant reductions in operating expenses, allowing for an extended cash runway. Notable publications from the global OGM community pointed to the technology's value in various diagnostic applications.
Read more →BNGOBionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies
Bionano Laboratories announced a significant publication detailing the largest study to evaluate the clinical utility of optical genome mapping (OGM) for hematologic malignancies. The study involved 519 samples and demonstrated that OGM revealed previously undetected somatic aberrations in 58% of cases and clinically relevant Tier 1 variants in 15% of cases. This could represent a transformative tool in cytogenetic diagnostics, potentially leading to improved patient outcomes through better detection of clinically significant variants. The findings underline the limitations of traditional cytogenetic methods, suggesting OGM may offer additional, critical insights for patient management.
Read more →BNGOBionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025
Bionano Genomics, Inc. announced plans to host a conference call and live webcast on May 14, 2025, at 4:30 p.m. Eastern Time. The call will focus on reporting the financial results for the first quarter of 2025 and discussing recent corporate progress. Investors can access the live webcast through the company's website.
Read more →BNGOBionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease
Bionano Genomics announced a significant peer-reviewed publication demonstrating that optical genome mapping (OGM) is an effective method for detecting and sizing large repeat expansions associated with various genetic disorders. The study, involving 85 subjects with known pathogenic expansions, highlighted OGM's high accuracy and efficiency, reporting a 98.8% detection rate. Additionally, it showcased the capability of OGM to measure extensive repeat sizes and revealed important insights into the somatic instability of these genetic conditions. This advancement is positioned to potentially enhance diagnostics and therapies for repeat expansion disorders.
Read more →BNGOBionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM
Bionano Genomics has announced a groundbreaking study published in The Journal of Molecular Diagnostics, detailing a new method for analyzing multiple myeloma using optical genome mapping (OGM). Researchers from Lille University Hospital identified that mixing CD138-positive and CD138-negative cells allows for a significant reduction in the required quantity of CD138-positive cells for effective analysis. This method boasts high concordance with traditional techniques while unveiling additional genetic events, streamlining laboratory processes and improving prognostic evaluations. This publication reflects an important step forward in the application of OGM in hematologic malignancies.
Read more →BNGOBionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025
Bionano Genomics, Inc. reported its financial results for Q4 and FY 2024, highlighting both challenges and milestones. Though revenues decreased by 24% in Q4 and 15% for the full year, the company noted significant reductions in operating expenses, achieving approximately $100 million in savings. The demand for its optical genome mapping products remains strong, bolstered by increased publication activity and a new CPT code aimed at improving reimbursement. Bionano also introduced various advancements in its technology aimed at enhancing operations and workflow efficiency.
Read more →BNGOBionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting
Bionano Genomics, Inc. (BNGO) announced its participation in the American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting, showcasing its optical genome mapping (OGM) technology. The event will feature multiple sessions led by experts discussing OGM's applications in hematological malignancies and genetic disorders. The presence of these expert presentations highlights the growing recognition and utility of OGM in clinical research. However, Bionano is currently managing a reduced operational footprint to control expenses, which may affect its market presence.
Read more →BNGOBionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025
Bionano Genomics, Inc. has announced it will report its financial results for the fourth quarter and full year of 2024 on March 31, 2025. The report will be followed by a conference call and live webcast to discuss the results and recent corporate developments. Participants will be able to access the webcast through Bionano's investor relations website. A replay of the conference call will be available for at least 30 days after the event.
Read more →BNGOBionano Announces Publication Reporting First Use of OGM to Detect Chromoanagenesis, a Key Marker of Poor Prognosis in AML
Bionano Genomics, Inc. announced a study published in the American Journal of Hematology that highlights the utility of optical genome mapping (OGM) for detecting chromoanagenesis (CAG) in acute myeloid leukemia (AML). The study found that CAG was present in 16% of analyzed AML cases and was associated with poor prognostic indicators. Researchers noted OGM's higher sensitivity compared to traditional cytogenetic methods, with implications for risk stratification and treatment planning in AML. The median survival for patients with CAG was significantly lower than those without it, indicating the need for timely therapeutic interventions.
Read more →BNGOBionano Announces Effective Date of Reverse Stock Split
Bionano Genomics announced a reverse stock split at a ratio of 1-for-60, which will take effect on January 24, 2025. This decision was approved during a special meeting of stockholders held on January 15, 2025, where the Board of Directors had the discretion to set the ratio between 1-for-25 and 1-for-75. The company's shares will begin trading under a new CUSIP number and on a split-adjusted basis on January 27, 2025. The move aims to consolidate shares and potentially improve stock value while acknowledging the inherent risks associated with future business operations and funding.
Read more →BNGOBionano Announces Use of OGM in Preimplantation Genetic Testing as Part of Successful Live Birth to a Couple Experiencing Recurrent Pregnancy Loss
Bionano Genomics has announced a successful case study where optical genome mapping (OGM) was used during preimplantation genetic testing, resulting in a healthy baby born to a couple with a history of recurrent pregnancy loss. OGM uniquely identified complex chromosomal rearrangements in the male partner that were missed by traditional cytogenetics, facilitating the selection of the most viable embryos. This innovative application of OGM may offer new hope for couples facing infertility challenges, as affirmed by Bionano's CEO Erik Holmlin.
Read more →BNGOBionano Reports Preliminary Fourth Quarter and Full-Year 2024 Results
Bionano Genomics, Inc. has reported preliminary financial results for Q4 and FY 2024, indicating a potential revenue decrease of around 25% over Q4 2023 due to the discontinuation of clinical service products. Despite this decline, the company saw a 14% increase in the installed base of optical genome mapping systems, leveraging advancements in OGM and VIA software. Additionally, Bionano reported raising capital to support its operations and restructure its financial obligations, aiming for improved profitability. The ongoing transition reflects significant changes implemented throughout the year.
Read more →BNGOBionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia
Bionano Genomics announced a publication from Johns Hopkins University demonstrating that Optical Genome Mapping (OGM) effectively identifies a critical structural variant associated with acute promyelocytic leukemia (APL). This variant, the PML::RARA fusion, is often missed by conventional cytogenetic methods. The study provides evidence that OGM may significantly enhance therapy selection for APL patients by detecting actionable variants more reliably than standard techniques. Bionano’s OGM technology is positioned as a viable alternative for better management of blood cancer cases.
Read more →BNGOBionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Bionano Genomics, Inc. has announced the successful closing of a $10 million registered direct offering. The offering included 39,682,540 shares of common stock and accompanying Warrants. The company plans to use the proceeds for general corporate purposes, including R&D and capital expenditures. There is uncertainty about the exercise of the Warrants and the attainment of Stockholder Approval, which could impact the overall financing strategy.
Read more →BNGOBionano Announces Amendment to Senior Secured
Bionano Genomics, Inc. has announced an amendment to its senior secured convertible debentures, which aims to enhance its financial position. The amendment defers near-term debt obligations and lowers monthly payment amounts through mid-2025. While it strengthens Bionano's capital structure and provides liquidity, it also introduces increased payment obligations starting in August 2025. The company remains focused on driving the adoption of its optical genome mapping technology.
Read more →BNGOBionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Bionano Genomics, Inc. has announced a $10 million registered direct offering priced at-the-market under Nasdaq rules, involving the sale of shares and warrants to institutional investors. This offering is expected to close on January 6, 2024, pending customary closing conditions. The net proceeds are intended for general corporate purposes, including R&D and repayment of existing debts. However, the company faces uncertainties surrounding stockholder approval and the potential exercise of the provided warrants.
Read more →BNGOBionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
Bionano Genomics has entered into an amendment to restructure its senior secured convertible debentures, which has extended the amortization schedule and reduced initial monthly payments from $1 million to $500,000. The restructuring aims to enhance the company's liquidity and financial flexibility, enabling it to further promote its optical genome mapping technologies. However, the subsequent increase in payments and lower conversion price raise concerns regarding potential future financial pressure and share dilution.
Read more →BNGOBionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis
Bionano Genomics has published a study from Johns Hopkins School of Medicine that shows their optical genome mapping (OGM) technique outperforms traditional cytogenetic assays in analyzing bone and soft tissue tumors. OGM consistently detected all variants identified by standard karyotyping and found several pathogenic variants that were previously missed. The study indicates a potential for OGM, when combined with next-generation sequencing, to significantly enhance the detection rate of pathogenic structural variants, thereby improving patient qualification for targeted therapies. This marks a significant development in the application of genomic mapping technology beyond hematologic malignancies.
Read more →BNGOBionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal
Bionano Genomics, Inc. has issued a letter to stockholders to gain support for proposals at its upcoming special meeting, particularly a reverse stock split. The company explains that this measure is crucial for compliance with Nasdaq's listing requirements, as its stock price has been below $1.00. Despite recent progress in their optical genome mapping business, Bionano's management emphasizes the need for continued investment and capital raising to sustain operations. A vote in favor of the proposal is being urged to ensure compliance and drive future progress.
Read more →BNGOBionano Announces Presentations at the American Society of Hematology (ASH) Annual Meeting that Underscore OGM Utility Across Blood Cancer Research and Cell & Gene Therapy
Bionano Genomics, Inc. announced the presentation of thirteen scientific posters at the American Society of Hematology (ASH) Annual Meeting, showcasing the utility of Optical Genome Mapping (OGM) in blood cancer research and cell & gene therapy. Among these, three posters were selected for sessions focused on Acute Myeloid Leukaemias (AML) and Acute Lymphoblastic Leukaemias (ALL). The conference, taking place in San Diego from December 7-10, 2024, highlights the importance of OGM and its potential role in improving diagnosis and treatment in hematological malignancies.
Read more →BNGOBionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress
Bionano Genomics reported its financial results for Q3 2024, showing a total revenue of $6.1 million, reflecting a 35% decrease compared to the same period last year. Despite the drop in revenue, there were increases in the installed base of optical genome mapping systems and in sales of nanochannel array flowcells. The company's cash burn has improved due to a restructuring plan aimed at expense reduction. Key highlights include progress in the implementation of CPT codes for OGM and new funding through direct placements.
Read more →BNGOBionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024
Bionano Genomics, Inc. has announced it will report its financial results for the third quarter of 2024 during a conference call and live webcast on November 13, 2024. The event is scheduled for 4:30 p.m. Eastern Time and will allow the company to share insights into its recent corporate progress. Participants can access the webcast live or listen to a replay afterward on Bionano's investor relations website.
Read more →BNGOBionano Announces $3 Million Registered Direct Offering Priced At- the-Market under Nasdaq Rules
Bionano Genomics has announced a $3 million registered direct offering priced at-the-market, which involves selling nearly 9.9 million shares of common stock along with Series C and D warrants. The offering aims to enhance Bionano's general corporate purposes, including research and development. However, the exercise of the warrants and completion of the offering depend on securing stockholder approval. The company outlines potential risks that might affect their financial outlook and ability to raise additional capital.
Read more →BNGOBionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Bionano Genomics, Inc. announced the closure of a $3 million registered direct offering for 9,881,113 shares of common stock and warrants. This offering, priced at $0.3039 per share, also includes options for additional gross proceeds of $6 million if the warrants are fully exercised. The funds raised will be used for general corporate purposes, including working capital and R&D. Potential risks include uncertainty regarding stockholder approval and the exercise of the warrants.
Read more →BNGOBionano Adjourns Special Meeting of Stockholders to November 27, 2024
Bionano Genomics, Inc. has adjourned its Special Meeting of Stockholders due to insufficient quorum participation, with only 30.7% of shares voted. The meeting will reconvene on November 27, 2024, allowing additional time for stockholders to cast their votes. Approximately 76.3% of the votes submitted thus far are in favor of the proposal. The absence of quorum poses significant risks for the company's future capital raising efforts if the proposal fails to pass.
Read more →BNGOBionano Announces Publication Outlining Utility of OGM for Resolution of MYC Gene Rearrangements in Multiple Myeloma
Bionano Genomics announced a publication demonstrating that optical genome mapping (OGM) can more effectively resolve MYC gene rearrangements in multiple myeloma compared to traditional cytogenetic methods. This advancement suggests a promising potential for wider adoption of OGM across all blood cancers, providing a more comprehensive understanding of the disease that could lead to improvements in precision medicine. The study emphasizes OGM’s efficiency in comparison to existing methods and its capability to reveal significant structural variations in genomic data. However, the publication also includes forward-looking statements that express uncertainties regarding the widespread adoption and success of OGM.
Read more →BNGOBionano Announces Preliminary 3Q 2024 Revenues and Cash
Bionano Genomics, Inc. has announced preliminary revenue figures for the third quarter of 2024, projecting earnings between $6.5 and $6.8 million, down from earlier estimates. The company holds approximately $23.3 million in cash and equivalents, with a significant portion subject to restrictions. CEO Erik Holmlin indicated a shift in strategy toward capital efficiency and increased utilization of their optical genome mapping (OGM) technology, which he believes may contribute to the revised revenue outlook. Future results may be adjusted based on ongoing financial reviews and market challenges.
Read more →BNGOBionano Adjourns Special Meeting of Stockholders to October 30, 2024
Bionano Genomics, Inc. has adjourned its Special Meeting of Stockholders initially held on October 2, 2024, due to insufficient votes for a quorum. As of that date, only 22.5% of outstanding shares had been voted, falling short of the 33.3% required. The meeting will reconvene on October 30, 2024, giving stockholders another opportunity to participate in the vote, with 74.5% of the votes cast thus far being in favor of the proposal. Company CEO Erik Holmlin emphasized the importance of stockholder participation for the company's future capital-raising efforts.
Read more →BNGOBionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
Bionano Genomics reported its Q2 2024 results, showing a 10% decrease in revenue to $7.8 million, alongside a 29% increase in the installed base of optical genome mapping (OGM) systems. The establishment of a new CPT code for OGM is expected to enhance its utility and market adoption. Despite challenges in revenue and flowcell sales, the company announced advancements in their technology, particularly with the Ionic Purification System. Financially, Bionano is focusing on long-term growth strategies while managing costs, indicating a goal to reduce annualized operating expenses significantly.
Read more →BNGOBionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting
Bionano Genomics, Inc. has announced its participation in the Cancer Genomics Consortium (CGC) 2024 Annual Meeting, where it will present on the utility of optical genome mapping (OGM) for hematological malignancies. Dr. Phillip Michaels from Harvard Medical School will discuss a multi-site study comparing OGM with classical cytogenetic methods. Additionally, various scientific posters will showcase the applications of OGM in blood cancer research. The conference will facilitate discussions on advancements in clinical genomics within the oncology field.
Read more →BNGOBionano to Present at the Canaccord Genuity 44th Annual Growth Conference
Bionano Genomics, Inc. announced that its CEO, Erik Holmlin, will present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024. This event will showcase Bionano's contributions to genome analysis solutions that assist researchers and clinicians. A webcast of the presentation will be available, followed by a recording for 30 days on the company’s website. This conference appearance highlights Bionano's commitment to advancing genomic understanding through its technologies.
Read more →BNGOBionano to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 7, 2024
Bionano Genomics, Inc. will host a conference call and a live webcast on August 7, 2024, to report its financial results for the second quarter of 2024. This event will occur at 4:30 p.m. Eastern Time and will also highlight the company’s recent corporate progress. Participants can access the live webcast and expect an archived replay on Bionano's investor relations website for at least 30 days.
Read more →BNGOBionano Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma
Bionano Genomics announced the publication of the first multi-site study comparing optical genome mapping (OGM) and traditional methods for analyzing multiple myeloma. Conducted by researchers from MD Anderson Cancer Center and Johns Hopkins Hospital, the study found that OGM significantly outperformed conventional cytogenetic techniques in detecting complex genomic rearrangements associated with cancer. Notably, OGM identified critical variants that altered prognostication in a substantial number of cases, suggesting its enhanced utility in cancer research. The results position OGM as a transformative tool in the analysis of genetic subtypes in multiple myeloma.
Read more →BNGOBionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Bionano Genomics, Inc. has announced the completion of a registered direct offering, generating approximately $10 million from the sale of over 17.5 million shares at a price of $0.571 each. The company also issued warrants that could yield an additional potential funding of about $20 million if exercised. The proceeds will be allocated for general corporate purposes, including research and development. However, the company faces uncertainties regarding the exercise of these warrants and requirements for stockholder approval.
Read more →BNGOBionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules $10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Serie
Bionano Genomics, Inc. announced a registered direct offering aiming to raise up to $30 million. This includes $10 million upfront and potential additional funds via clinical milestone-linked Series Warrants. The offering is priced at $0.571 per share and is contingent upon stockholder approval. The proceeds are intended for corporate purposes, including R&D and debt repayment, while the actual execution remains subject to closing conditions.
Read more →BNGOBionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting
Bionano Genomics, Inc. (NASDAQ: BNGO) will present its optical genome mapping (OGM) technology at the ISSCR Annual Meeting in Hamburg, Germany, from July 10-13, 2024. The company will showcase the utility of OGM for enhancing genome integrity and minimizing off-target effects in stem cell therapy through expert presentations and scientific posters. Notable speakers include researchers from prominent institutions like Ruhr University Bochum and Scripps Research Institute. The event aims to foster discussions on integrating OGM in developing safer and more effective therapies.
Read more →BNGOBionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
Bionano Genomics has formed a marketing agreement with Revvity to promote its VIA software within Revvity's newborn sequencing research workflow. This collaboration aims to enhance the assessment of copy number variation in sequencing results and streamline interpretation capabilities. Bionano's VIA software will be utilized as part of Revvity's end-to-end solution, which includes DNA extraction and sequencing. This development signifies a move towards integrating advanced genomic solutions into newborn screening processes.
Read more →BNGOBionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis
Bionano Laboratories has announced the establishment of a new Category I CPT code for optical genome mapping (OGM) in the analysis of hematological malignancies, as approved by the American Medical Association. This code is crucial for securing reimbursement for the OGM-Dx HemeOne test from third-party payers, with implementation expected by January 1, 2025. The decision reflects a significant endorsement of OGM technology, distinguishing it from emerging technologies that receive Category III codes, thereby improving its clinical acceptance and potential market adoption.
Read more →BNGOBionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow
Bionano Genomics will make a significant impact at the upcoming 2024 European Society for Human Genetics (ESHG) and American Cytogenomics Conference (ACC) with a total of 39 scientific presentations and posters. These presentations will cover the utility of optical genome mapping (OGM) in research related to genetic disorders, rare diseases, and cancer. Notable presentations include discussions from leading researchers on OGM's abilities to enhance genetic disease detection and provide insights into hereditary conditions. Bionano's advancements, including the introduction of the Stratys system and VIA software, will be featured prominently in these sessions.
Read more →BNGOBionano Announces Private Placement of Senior Secured Notes in Debt Restructuring that Improves Balance Sheet Provides significant financial flexibility by` retiring near-term debt maturities, deferring principal redempt
Bionano Genomics Inc. has completed a private placement of senior secured convertible debentures due May 2026, raising $18 million. This financing allows the company to retire existing convertible debt and significantly improve its balance sheet and liquidity position. The restructuring is part of a broader strategic initiative established earlier this year, enabling the company to enhance its operations and drive the adoption of its optical genome mapping technology. Additional details about the placement will be shared in a forthcoming SEC filing.
Read more →BNGOBionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy
Bionano Genomics (BNGO) announced the publication of three studies demonstrating the growing support for optical genome mapping (OGM) as a vital tool in the development of cell and gene therapies. These publications show that OGM can detect structural variants with more sensitivity and resolution compared to traditional techniques, thereby enhancing genome integrity assessment in therapeutic cell lines. Despite some concerns about the genotoxicity of certain CAR-T products, the studies provide confidence in OGM's ability to assist researchers in ensuring the quality of gene edits linked to various diseases, including Alzheimer’s.
Read more →BNGOBionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
Bionano Genomics has announced major upgrades to its computational tools aimed at comprehensive cancer analysis. The enhancements to its VIA™ software improve the detection and interpretation of genomic abnormalities, including aneusomies, with increased sensitivity and precision. New features such as automated analysis and improved visualization tools will help researchers in accurately identifying critical cancer signatures. These advancements are expected to streamline processes for analyzing and reporting genomic data in research settings.
Read more →BNGOBionano Reports First Quarter 2024 Results and Highlights Recent Business Progress
Bionano Genomics reported an 18% increase in revenue for Q1 2024, totaling $8.8 million. The company also saw a 34% increase in the installed base of optical genome mapping systems and a noteworthy 58% growth in nanochannel array flowcell sales. Bionano continues to implement cost-saving initiatives, including a reduction in workforce, to improve cash burn and operating expenses. Additionally, a strategic partnership was announced aimed at commercializing an integrated cytogenetic workflow with AI capabilities.
Read more →BNGOBionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
Bionano Genomics, Inc. has announced a conference call scheduled for May 8, 2024, where it will report its financial results for the first quarter of 2024. The call will take place at 4:30 p.m. ET and will also highlight the company's recent corporate developments. Participants can access the live webcast through Bionano's website, and a replay will be available for at least 30 days afterward.
Read more →BNGOBionano to Present at the RBC Capital Markets 2024 Global Healthcare Conference
Bionano Genomics, Inc. announced that its CEO, Erik Holmlin, PhD, will present at the RBC Capital Markets 2024 Global Healthcare Conference on May 15, 2024. This presentation signifies an opportunity for the company to highlight its genome analysis solutions and advances in the field. Attendees can register for the event online, and a recording will be available on Bionano's website for 30 days post-conference. The focus will be on the company's mission to transform genome analysis through various technologies and services.
Read more →BNGOBionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
Bionano Genomics, Inc. announced positive results from a study comparing optical genome mapping (OGM) with traditional cytogenetic methods for detecting structural variants in leukemia samples. The study, conducted by researchers at University Medical Center Groningen, showed that OGM frequently identifies variants overlooked by conventional techniques. Using targeted Cas9-directed Nanopore sequencing for validation, researchers confirmed the OGM findings, contributing to a more comprehensive understanding of leukemia subtypes. Bionano views this advancement as a significant step towards enhancing genomic analysis in blood cancer.
Read more →BNGOBionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
Bionano Genomics has formed a strategic partnership with Hangzhou Diagens Biotechnology to pioneer a new cytogenetic workflow combining optical genome mapping and AI chromosome karyotype analysis. This collaboration aims to enhance the detection of pathogenic structural variants linked to reproductive health issues such as recurrent pregnancy loss. Diagens has already secured approval for Bionano’s reagents from China's NMPA, and plans to register the Saphyr instrument for clinical use. The move is expected to improve success rates in in vitro fertilization and expand into broader applications in the future.
Read more →BNGOBionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing
Bionano Genomics, Inc. announced a study from Penn State College of Medicine demonstrating that optical genome mapping (OGM) identified over 1,250 structural variants in pediatric B-cell acute lymphoblastic leukemia not detected by whole genome sequencing (WGS). The study highlighted the advantage of combining OGM with WGS, showing that OGM also uncovered 56 gene fusions missed by WGS. These findings suggest OGM could serve as a powerful tool for improving personalized medicine and identifying new therapeutic targets in pediatric leukemia.
Read more →BNGOBionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Bionano Genomics, Inc. announced a registered direct offering to sell approximately 8.73 million shares priced at $1.145 each, aiming to raise $10 million for corporate purposes, including working capital and R&D. The offering, facilitated by H.C. Wainwright & Co., is set to close around April 8, 2024, pending customary conditions. This move highlights Bionano's efforts to bolster its financial standing, but it comes with inherent market risks and uncertainties.
Read more →BNGOBionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics
Bionano Genomics has announced the publication of a peer-reviewed study showcasing the efficacy of Optical Genome Mapping (OGM) in detecting genetic aberrations in sarcoma samples. The study found that OGM not only demonstrated a high level of concordance with traditional cytogenetic methods, but also identified pathogenic alterations missed by these classical techniques. With its ability to detect alterations at a significantly higher resolution, OGM may enhance the diagnostic capabilities for addressing the complex genetic landscape of sarcomas. The findings are expected to contribute to better tumor characterization and treatment approaches in oncology.
Read more →BNGOBionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting
Bionano Genomics (BNGO) is set to participate in the 2024 American Association for Cancer Research Annual Meeting, where it will present nine scientific posters highlighting the utility of optical genome mapping (OGM) in cancer research. The company will introduce its new high throughput Stratys system and preview advancements in its VIA 7.1 software, designed to enhance cancer research capabilities. The event aims to foster discussions on the advancements in cancer science and the potential clinical applications of OGM. The annual meeting will take place from April 5-10, 2024, in San Diego, California.
Read more →BNGOBionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
Bionano Genomics has published a study on optical genome mapping (OGM) in hereditary breast and ovarian cancer syndrome, indicating that a higher count of structural variations (SVs) in tumors correlates with poorer prognosis and resistance to chemotherapy. The study found that OGM could accurately detect chromothripsis events and novel gene fusions, some of which were not identified by other techniques. Results suggest that the classification of tumors based on SV counts may carry predictive and therapeutic significance in breast cancer. This advancement may enhance the approach to personalized medicine and improve patient outcomes.
Read more →BNGOBionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System
Bionano Genomics, Inc. will participate in the ACMG Annual Meeting 2024, showcasing its new Stratys system for optical genome mapping. The event will feature a live product demo and presentations by leading researchers discussing the system's applications in various genetic disorders. Bionano's CEO will present a corporate overview, and the conference is expected to attract professionals from academia and industry to discuss advancements in clinical genetics. The conference will take place in Toronto, Canada from March 12-16, 2024.
Read more →BNGOBionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024
Bionano Genomics, Inc. reported significant financial results for Q4 and full-year 2023, with revenues of $10.7 million and $36.1 million, respectively, reflecting a 30% increase from the previous year. The company achieved a 36% growth in the installed base of optical genome mapping (OGM) systems and saw a substantial rise in flowcell sales. With new product releases and a positive outlook for 2024, Bionano aims to continue its trajectory of growth despite ongoing high operating expenses and the strategic discontinuation of certain legacy products. Upcoming milestones include a projected revenue range for 2024 and an expected increase in OGM system installations.
Read more →BNGOBionano to Present at TD Cowen’s 44th Annual Health Care Conference
Bionano Genomics, Inc. will be presenting at TD Cowen's 44th Annual Health Care Conference on March 6, 2024. CEO Erik Holmlin, PhD, will lead the presentation, focusing on the company's advancements in genome analysis solutions. Bionano aims to transform genome visualization through its optical genome mapping technologies and diagnostic services. Following the conference, a recording of the session will be available for at least 30 days on the company's website.
Read more →BNGOBionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway - Amendment Reduces Bionano's Outstanding Debt
Bionano Genomics has announced an amendment to its convertible debt financing arrangement, which helps to extend its cash runway while reducing outstanding debt. The company now has approximately $24.3 million in principal of the Initial Registered Note outstanding, and the new arrangement immediately provides access to $30 million in liquidity. This move is aimed at enhancing financial flexibility and supports the company's path toward profitability while further capitalizing on its optical genome mapping technologies.
Read more →BNGOBionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024
Bionano Genomics, Inc. has announced a conference call and live webcast set for March 5, 2024, at 4:30 p.m. Eastern Time. The event will provide financial results for the fourth quarter and full year of 2023, along with updates on recent corporate progress. Participants can access the live call through the company's investor relations page.
Read more →BNGOBionano to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Bionano Genomics, Inc. has announced that its president and CEO, Erik Holmlin, will take part in the upcoming BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference scheduled for February 13-14, 2024. The event presents an opportunity for Bionano to promote its advanced genome analysis solutions and diagnostic services. Stakeholders interested in meeting with Bionano during the conference can schedule virtual or in-person meetings through BTIG representatives. The company continues its mission to improve how the genome is understood with its innovative technologies.
Read more →BNGOBionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS
Bionano Genomics held its 2024 Symposium from January 22-25, featuring 32 oral presentations and 69 scientific posters highlighting the advancements in optical genome mapping (OGM). The event attracted over 2,100 registrants from 92 countries, focusing on a wide range of applications, including cancer research and genetic diseases. Presenters emphasized OGM's potential to replace classical cytogenetic methods, offering higher sensitivity and new insights into treatment options. The on-demand presentations will remain available throughout 2024, allowing further engagement with the research shared.
Read more →BNGOBionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer
Bionano Genomics announced a peer-reviewed publication demonstrating the use of optical genome mapping (OGM) to discover structural variants associated with drug resistance and sensitivity in leukemia. The study found that OGM detected all known structural variants and revealed additional ones that could influence therapeutic outcomes. These findings suggest the potential for developing new treatment strategies and underline OGM's advantages over traditional methods. The publication represents a notable advancement in understanding the genetic factors affecting leukemia treatment efficacy.
Read more →BNGOBionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing
Bionano Genomics has published the second interim results of its clinical trial validating Optical Genome Mapping (OGM) for prenatal testing as a potential standard of care. The results indicate that OGM offers comparable accuracy to traditional cytogenetic methods, with an overall accuracy of 99.6% and full concordance in many cases. Notably, OGM could fulfill the diagnostic requirements usually met by two or three separate traditional assays with just one test. This progress supports the argument for OGM's inclusion in prenatal genetic testing standards.
Read more →BNGOBionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping
Bionano Genomics has announced the full commercial release of its Stratys™ system for high throughput optical genome mapping. The new system shows significant improvements, offering up to four times the data generation rate compared to the previous Saphyr® instrument and is designed to cater to both mid and high-volume laboratory needs. Early access programs have showcased strong interest, with multiple institutions already adopting the system. The introduction of the Stratys Compute workstation enhances data analysis capabilities, leveraging advanced processing technologies.
Read more →BNGOBionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
Bionano Genomics, Inc. has announced its lineup for the 2024 Symposium, featuring 33 oral presentations from 26 customers globally. The event will highlight the application of optical genome mapping (OGM) in various fields such as cancer, gene therapy, and genetic diseases. Scheduled to take place virtually from January 22 to January 25, attendees will have the opportunity to engage in live panels and view scientific posters. Notably, a new product will be unveiled during the event aimed at enhancing cytogenetics and structural variant analysis.
Read more →BNGOBionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing
Bionano Genomics, Inc. has announced the publication of results from the second phase of a clinical study on its optical genome mapping (OGM) technology. This study involved 627 samples and demonstrated a 99.5% concordance rate for detecting pathogenic variants compared to standard of care methods. OGM showed improved detection rates for pathogenic variants, increasing by 6% to 50% depending on patient population. The findings suggest that OGM could be a viable addition to the standard of care for diagnosing genetic disorders, particularly in challenging cases involving pediatric intellectual disabilities and autism spectrum disorder.
Read more →BNGOBionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
Bionano Genomics, Inc. has announced its upcoming 2024 Symposium scheduled from January 22 to 25, 2024, featuring four days of presentations and panel discussions focused on optical genome mapping (OGM). The event will showcase 27 presentations from researchers around the world, covering applications in cancer, cell and gene therapy, and genetic diseases. Notably, a new product related to cytogenetics will be unveiled during the symposium. The 2024 event builds on the successful engagement seen in the previous year, indicating strong global interest in OGM research.
Read more →BNGOBionano Reports Preliminary Fourth Quarter and Full-Year 2023 Results Preliminary Q4 2023 revenue expected to be between $10.4 and $10.7 million, which would represent an estimated increase of 27% to 30% over Q4 2022 Rea
Bionano Genomics announced preliminary financial highlights for Q4 and full-year 2023, expecting revenues between $10.4 million and $10.7 million, up 27% to 30% from Q4 2022. The company reported achieving all its ELEVATE milestones and noted progress in advancing its optical genome mapping (OGM) technology. However, its figures are preliminary and subject to change, highlighting uncertainties around financial performance as they finalize their year-end reporting process.
Read more →BNGOBionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research
Bionano Genomics has announced significant upgrades to its Bionano Solve pipeline and VIA software for analyzing optical genome mapping (OGM) data. The enhancements focus on improving sensitivity and specificity for detecting structural variations and copy number variants, facilitating comprehensive data visualization and report generation. The updates particularly benefit researchers working in constitutional genetic disease research, allowing for enhanced automated analysis and interpretation aligned with established guidelines and databases. This advancement is expected to empower researchers to tackle larger, more complex projects efficiently.
Read more →BNGOBionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping
Bionano Genomics has published findings from the largest prospective prenatal study comparing its optical genome mapping (OGM) technology to traditional methods, including chromosomal microarray analysis (CMA) and karyotyping (KT). The study evaluated 200 prenatal samples and found that OGM had superior performance metrics, achieving high sensitivity and specificity along with the ability to detect structural variants and copy number variants that other methods overlooked. With its promising capabilities, OGM is positioned as a potential first-tier cytogenetic method for prenatal analysis.
Read more →BNGOBionano Laboratories Announces Publication of the Analytical Validation of its OGM-Based Laboratory Developed Test for Hematological Malignancies and Additional Multi-Site Technical Evaluation of OGM
Bionano Laboratories has published a study validating its OGM-Dx HemeOne laboratory-developed test (LDT) for hematological malignancies. The test utilizes optical genome mapping to detect structural variants (SVs) with 100% concordance compared to traditional methods. The study involved multi-site evaluations and showed that OGM could lead to improved diagnostic yields, including the identification of previously unreported pathogenic variants. The test is positioned as a promising alternative to traditional cytogenetic methods, although uncertainties regarding implementation and future validations remain.
Read more →BNGOBionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual Meeting
Bionano Genomics announced that its optical genome mapping (OGM) technology will be highlighted at the upcoming American Society of Hematology Annual Meeting. Several presentations and posters will focus on OGM's applications in blood cancer research, including multiple myeloma and acute lymphoblastic leukemia. This conference, taking place from December 9-12, 2023, in San Diego, aims to facilitate discussions among industry professionals about advancements in blood disease treatments. Notably, Dr. Enze Liu will present findings on OGM's role in detecting structural variants related to disease progression in multiple myeloma.
Read more →BNGOBionano Announces Publication Demonstrating Utility of OGM to Assess Genome Integrity of CRISPR-Edited Cells as Part of Gene Therapy Development
Bionano Genomics (BNGO) has announced the publication of a research study that showcases the effectiveness of Optical Genome Mapping (OGM) for assessing genome integrity in CRISPR-edited CD4+ T-cells. The study indicates that OGM is superior to traditional karyotyping and can detect significant structural variations that other methods, such as ddPCR, might miss. This advancement could enhance the quality control processes in gene therapy development by identifying both on-target and off-target effects early in the development phase. The findings suggest that OGM's integration could potentially streamline the analysis process in the manufacturing of gene therapies.
Read more →BNGOBionano Announces Presentation of OGM Utility Across Key Research Applications at the Association for Molecular Pathology Annual Meeting
Bionano Genomics, Inc. (BNGO) announced its participation in the AMP 2023 Annual Meeting, showcasing the utility of optical genome mapping (OGM) across various research applications. Notable sessions will include presentations on OGM's role in CNS tumor analysis and hematological malignancies. The event will feature Bionano leadership discussing innovative workflows and new product developments. Furthermore, several scientific posters will provide insights into OGM applications in cancer and genetic research at the conference scheduled for November 14-18, 2023, in Salt Lake City, Utah.
Read more →BNGOBionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress
Bionano Genomics reported its third quarter 2023 financial results, revealing a revenue increase of 29% year-over-year, amounting to $9.3 million. The company achieved a significant 39% growth in its installed base of Saphyr systems and sold 6,176 nanochannel array flowcells, marking a 55% rise from the previous year. Bionano also completed an $80 million financing to bolster its operations and announced operational efficiency initiatives to reduce expenses. Despite the positive growth metrics, the company faced rising operational expenses, including significant GAAP-only charges, which may pose financial risks moving forward.
Read more →BNGOBionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023
Bionano Genomics, Inc. will host a conference call and live webcast on November 8, 2023, at 4:30 p.m. ET to discuss its third quarter financial results. The event will also highlight recent corporate progress. Participants can access the call online, and a replay will be available for at least 30 days on the company’s investor relations website.
Read more →BNGOBionano to Present at the 2023 Stifel Healthcare Conference
Bionano Genomics, Inc. has announced that its CEO, Erik Holmlin, PhD, will present at the 2023 Stifel Healthcare Conference on November 15, 2023. This event will showcase the company’s advancements in genome analysis solutions. Bionano is focused on transforming genomic understanding through various products and services, including diagnostic testing for autism spectrum disorder. A recording of the session will be available on the Bionano website after the conference.
Read more →BNGOBionano Announces Presentation of OGM Utility Across Key Applications at the American Society of Human Genetics (ASHG) Annual Meeting
Bionano Genomics, Inc. (BNGO) is set to participate in the American Society of Human Genetics (ASHG) Annual Meeting 2023, featuring a range of presentations on optical genome mapping (OGM) applications in genetic research. The sessions will cover various applications, including neurodevelopmental and prenatal research, as well as quality control in cell manufacturing. Notably, significant findings from major studies comparing OGM to traditional cytogenetic methods will be discussed by leading researchers in the field. The conference, taking place in Washington, D.C., from November 1-5, 2023, promises to showcase advancements in clinical genomics.
Read more →BNGOBionano Announces Pricing of $80.0 Million Registered Offering and Concurrent Private Placement of Senior Secured Convertible Notes and Warrants
Bionano Genomics, Inc. has announced the pricing of an $80 million registered offering, including $45 million in senior secured convertible notes and a concurrent $35 million private placement. Each note includes warrants to purchase shares of common stock, with provisions for conversion and early redemption. The financing aims to enhance the company's capital position as it pursues its mission in genome analysis. The offerings hinge on closing conditions and are set to secure Bionano's financial future leading into 2025.
Read more →BNGOBionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan
Bionano Genomics reported an $80 million financing through a registered offering and private placement of convertible notes and warrants. Preliminary Q3 2023 results indicate expected revenue growth of 26% to 29% year-over-year, alongside a substantial increase in the installed base of Saphyr systems and flowcells sold. To enhance profitability, the company is undertaking cost-saving measures that include a reduction in workforce projected to save about $33 million annually. These financial updates come amidst a difficult financing environment, necessitating strategic measures for long-term sustainability.
Read more →BNGOBionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan Bionano announced today that it has priced a financing to raise
Bionano Genomics announced the pricing of an $80 million financing through convertible notes and warrants, aimed at extending the company's cash runway amidst a challenging financial environment. The company also reported strong preliminary financial results for Q3 2023, indicating growth in revenues and an increase in the installed base of its optical genome mapping systems compared to the previous year. Additionally, Bionano implemented cost-saving measures as part of its operational streamlining, which are crucial for achieving profitability. However, the company warns that its preliminary financial figures are subject to adjustments and should be viewed cautiously.
Read more →BNGOBionano Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Bionano Genomics, Inc. announced an inducement grant on September 18, 2023, for their new Chief Financial Officer, Gülsen Kama. The grant consists of a non-qualified stock option for 106,000 shares at an exercise price of $3.00, aligning with the company's stock price at the time. The award will vest over four years, supporting the company's incentive strategy to attract and retain talent. Bionano aims to enhance its genomic analysis solutions and expand its diagnostic services through this leadership appointment.
Read more →BNGOBionano Announces Third OEM Partner has Received China NMPA Approval for DNA Isolation Products for IVD Use of OGM
Bionano Genomics announced that its OEM partner, Ecobono, has obtained NMPA approval for DNA isolation kits intended for in vitro diagnostics in China. This marks Ecobono as Bionano's third Chinese OEM partner to gain such approval, facilitating the sale of optical genome mapping reagents to clinical laboratories and hospitals. The CEO of both companies expressed optimism about future milestones and the impact of this approval on reproductive health research in China.
Read more →BNGOBionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and WES for Evaluation of Pediatric Leukemia
Bionano Genomics, Inc. has announced a peer-reviewed publication detailing a study from the German Cancer Consortium that highlights the effectiveness of optical genome mapping (OGM) combined with whole-exome sequencing (WES) in evaluating pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The research involved 60 pediatric samples and revealed that this combination significantly improves the understanding of mutational profiles and identifies novel genetic abnormalities that may drive the disease. These findings could impact risk stratification and management for pediatric leukemia, suggesting potential advancements in treatment pathways.
Read more →BNGOBionano Announces Publication Demonstrating Utility of OGM as an Alternative to KT and CMA for Evaluating CRISPR-Edited Cells as Part of Stem Cell Therapy Development
Bionano Genomics has published a study in Nature Communications that explores the potential of optical genome mapping (OGM) as an alternative to traditional methods for evaluating CRISPR-Cas9 edited human induced pluripotent stem cells (iPSCs). The research identifies that 15% of the edited genomes contained significant deletions, highlighting the risk of off-target effects. This establishes a critical need for detailed analysis of genomic alterations in the context of developing cell and gene therapies, particularly in stem cell applications. Bionano aims to utilize these findings to enhance safety in stem cell therapies using its genome analysis solutions.
Read more →BNGOBionano Announces Second OEM Partner has Received China NMPA Approval for DNA Extraction and Labeling Products for IVD Use of OGM in Reproductive Health
Bionano Genomics announced that its OEM partner, A-smart MedTech, has received NMPA approval for DNA extraction and labeling kits intended for use in reproductive health diagnostics in China. This marks the second OEM partner of Bionano to gain such approval, allowing A-smart to sell these reagents to clinical laboratories and hospitals in the region. The announcement highlights Bionano's commitment to enhancing reproductive health solutions through advanced genomic technologies, anticipating an increase in sales for its optical genome mapping systems as a result.
Read more →BNGOBionano Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
Bionano Genomics, Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement, as its stock closed at $1.00 or greater for ten consecutive business days. The compliance notification comes after a previous letter from Nasdaq on May 30, 2023, stating that the company was not meeting this requirement. With this recent compliance, the company can continue its listing on the Nasdaq Capital Market without further issues regarding the minimum bid price.
Read more →BNGOBionano Laboratories Receives College of American Pathologists (CAP) Accreditation for its Clinical Laboratory
Bionano Laboratories has been accredited by the College of American Pathologists (CAP), which is crucial for its CLIA-certified reference lab. This accreditation is significant for clinical service providers, as it can facilitate inclusion in insurance company reimbursement networks. It is also highly regarded among pharmaceutical and biotechnology firms, supporting projects under a robust regulatory framework. Company executives expressed pride in achieving this milestone, emphasizing its potential impact on the proliferation of optical genome mapping in various markets.
Read more →BNGOBionano Announces CFO Transition and Appointment of G lsen Kama as Chief Financial Officer
Bionano Genomics, Inc. has announced the appointment of G lsen Kama as its new Chief Financial Officer, effective September 11, 2023. Kama brings a wealth of experience from her previous roles at Northern Data AG and Quest Diagnostics, where she demonstrated expertise in financial strategy and operational efficiency. Current CFO Christopher Stewart will assist during the transition before moving to an advisory role. The leadership team is optimistic about Kama's ability to drive the company towards profitability and enhance its operations in cytogenetics.
Read more →BNGOBionano Announces Presentation of Optical Genome Mapping (OGM) Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting
Bionano Genomics, Inc. (Nasdaq: BNGO) announced its participation in the Cancer Genomics Consortium (CGC) 2023 Annual Meeting, where it will present on the utility of optical genome mapping (OGM) across various cancer research applications. Highlights include thirteen scientific presentations and a panel discussion featuring leading experts in cancer genomics. Bionano will introduce its latest products, including Ionic G2 kits and VIA software, aimed at improving workflows in clinical research. The conference, held from August 13-16 in St. Louis, Missouri, serves as a platform for professionals in clinical genomics to discuss advancements in the field.
Read more →BNGOBionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress
Bionano Genomics, Inc. reported strong financial results for the second quarter of 2023, with revenues reaching $8.7 million, a 30% increase year-over-year. The company saw a 43% growth in its installed base of Saphyr systems and a significant increase in the sales of flowcells. New product releases, including the Stratys system and enhancements to the Ionic Purification System, are expected to boost future revenue. However, the company also reported rising operating expenses and a decrease in cash reserves compared to the previous quarter.
Read more →BNGOBionano Genomics Announces Reverse Stock Split
Bionano Genomics has announced a reverse stock split at a ratio of 1-for-10, effective on August 4, 2023. This decision follows approval from stockholders during the annual meeting held on June 14, 2023, and aims to enhance the company's stock price. Following the split, trading will commence on a split-adjusted basis on August 7, 2023, with shareholders' common stock holdings adjusted accordingly. The company cautions that forward-looking statements about the split's impact carry inherent risks.
Read more →BNGOBionano to Report Second Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 9, 2023
Bionano Genomics, Inc. has announced a conference call and live webcast scheduled for August 9, 2023, at 4:30 p.m. ET. The purpose of the call is to report financial results for the second quarter of 2023 and to highlight recent corporate progress. Investors will be able to access the live event on the Bionano website, and a replay will be available for at least 30 days thereafter.
Read more →BNGOBionano Announces OGM Roadshow, TOUR, which Provides Education on the Company’s Workflow and Helps Build a Community of Users
Bionano Genomics has launched an optical genome mapping (OGM) roadshow named Bionano TOUR, aimed at educating users on OGM workflows and applications. The event series has already covered 8 U.S. cities, receiving positive feedback from participants, including scientists and clinical researchers. Additionally, the roadshow seeks to strengthen the community of OGM users and explore new avenues for research in various fields. Bionano's products promise to provide enhanced insights into genomic analysis, particularly for hematological diseases and genetic disorders.
Read more →BNGOBionano to Present at the Canaccord Genuity 43rd Annual Growth Conference
Bionano Genomics, Inc. announced that its CEO, Erik Holmlin, will present at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023. The conference aims to connect institutional investors with promising growth companies. Bionano specializes in genome analysis solutions and offers diagnostic services and software to support researchers and clinicians. This presentation is expected to elevate the company's visibility in the biotechnology sector.
Read more →BNGOBionano Announces the Stratys™ System for OGM and VIA™ Software for Hematologic Malignancies
Bionano Genomics has launched the Stratys™ system and VIA™ software designed to improve optical genome mapping (OGM) and streamline data interpretation for hematologic malignancies. The Stratys system offers a four-fold increase in data generation rates compared to the existing Saphyr instrument, aiming for further improvements with potential for a 13-fold increase through multi-instrument work-cells. The VIA software enhances the analysis of OGM, NGS, and microarray data, providing a unified reporting platform. The commercial rollout of the first 10 Stratys systems and installations of VIA are set to begin in the latter half of 2023.
Read more →BNGOBionano to Present at the Healthcare Virtual Conference
Bionano Genomics, Inc. (BNGO) announced its participation in the Healthcare Virtual Conference hosted by M-Vest and Maxim Group LLC. CEO Erik Holmlin is scheduled to present a company overview and engage in a fire-side chat during the event. The company, known for innovative genome analysis solutions, aims to transform genomic insights through its advanced offerings. Bionano also provides diagnostic services for neurodevelopmental disabilities, enhancing its role in the healthcare sector.
Read more →BNGOBionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and a 523-gene NGS Panel for Standard Evaluation of Myeloid Cancers
Bionano Genomics announced a peer-reviewed study demonstrating the effectiveness of combining optical genome mapping (OGM) with a 523-gene next-generation sequencing (NGS) panel for evaluating myeloid cancers. Conducted by Augusta University, the study highlights significant improvements in identifying structural variations compared to traditional cytogenetic methods. Notably, OGM found clinically relevant structural variations in a significant portion of previously classified normal cases. The research indicates that this combined approach could lead to better patient outcomes through more accurate disease stratification.
Read more →BNGOBionano Announces Results from its Annual Meeting of Stockholders
Bionano Genomics, Inc. held its 2023 Annual Meeting of Stockholders, where all proposed resolutions were approved. CEO Erik Holmlin expressed appreciation for the stockholders' support and underscored the company's commitment to executing its strategy. Bionano provides advanced genome analysis solutions and diagnostic testing services, aiming to transform genomic insights for research and clinical applications.
Read more →BNGOBionano Announces 2023 Winners of its Innovator Research Grant Program
Bionano Genomics announced the winners of its 2023 Innovator Research Grant program, recognizing Dr. Michael Khodadoust from Stanford as the grand prize winner. The program awarded several research initiatives that aim to leverage Bionano's optical genome mapping (OGM) technology for cancer and genetic disease studies. Other notable winners include Dr. Afia Hasnain and Dr. Stefan Rentas, who are investigating acute lymphoblastic leukemia and central nervous system tumors, respectively. The program highlights Bionano's commitment to fostering innovative research projects from a global pool of applicants.
Read more →BNGOBionano Announces Extensive Lineup of Content at European Conferences Featuring OGM Utility Across a Broad Range of Research Applications
Bionano Genomics, Inc. announced a prominent presence at several major European cytogenetic conferences, highlighting their optical genome mapping (OGM) technology. This technology will be featured in multiple presentations and scientific posters across various research areas, including genetic disorders and cancer. Significant discussions will take place on the applications of OGM, emphasizing its utility in advancing research and potential clinical applications. Bionano's CEO expressed pride in the ongoing research and development efforts in the human genetics space, underscoring OGM's expanding role in clinical studies.
Read more →BNGOBionano Announces Commercial Release of New Kits for its Ionic System featuring New Chemistry for Nucleic Acid Extraction from FFPE and Tumor Tissue
Bionano Genomics has announced the commercial release of new kits for its Ionic Purification System, featuring advanced chemistry to enhance nucleic acid extraction from FFPE and tumor tissues. These kits promise to increase yield and quality of nucleic acids from challenging samples, with expectations of improved outcomes for next-generation sequencing applications. However, the company acknowledges potential risks concerning the adoption of these kits and the efficacy of the purification process in varied real-world scenarios.
Read more →BNGOBionano Reports First Quarter 2023 Results and Highlights Recent Business Progress
Bionano Genomics reported a record revenue of $7.4 million for Q1 2023, reflecting a 30% increase compared to Q1 2022. Key highlights include a 47% increase in the installed base of Saphyr systems and a successful collaboration with NVIDIA aimed at improving data processing in optical genome mapping. However, operating expenses rose significantly, prompting strategic measures to reduce cash expenditures by approximately $20 million. Despite this, the company maintains positive momentum in its growth initiatives and product adoption.
Read more →BNGOBionano to Report First Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 9, 2023
Bionano Genomics, Inc. has announced a conference call and live webcast scheduled for May 9, 2023, at 4:30 p.m. ET to report its financial results for the first quarter of 2023. During the call, the company will also discuss recent corporate advancements. Investors can access the live call via a toll-free number, and a recorded version will be available on the company's investor relations website for at least 30 days.
Read more →BNGOBionano Announces Three Publications Demonstrating OGM’s Utility for Hematological Malignancy Research
Bionano Genomics, Inc. (BNGO) announced the publication of three studies highlighting the efficacy of optical genome mapping (OGM) as a significant alternative to traditional cytogenetic methods for hematological malignancies. The studies indicate that OGM not only matches but can surpass traditional methods in sensitivity and the detection of genetic variants, potentially impacting patient management positively. These findings consolidate OGM's role as a first-tier cytogenetic test in clinical settings, offering rapid and comprehensive results critical for therapy selection and risk assessment.
Read more →BNGOUPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 202
Bionano Genomics has announced preliminary financial results for Q1 2023, expecting total revenue between $7.3 million and $7.5 million, marking a significant growth of 28% to 32% from the previous year. The company emphasizes its continued momentum, having achieved consistent revenue growth for over ten quarters. While the results are positive, they remain preliminary and unaudited, which may lead to material differences once final figures are disclosed. Bionano is also focusing on expanding its product portfolio and increasing market awareness of its optical genome mapping (OGM) technologies.
Read more →BNGOBionano Announces Preliminary Q1 2023 Results and Business Updates
Bionano Genomics (BNGO) announced preliminary financial results for Q1 2023, reporting expected revenues between $7.3 million and $7.5 million, which reflects a rise of 28% to 32% from the previous year. The company also noted a 47% increase in its installed base of Saphyr systems and a significant growth in flowcell sales. Additionally, Bionano withdrew applications for Category I CPT codes for its optical genome mapping technology, aiming to avoid potential negative implications. Overall, Bionano marks its tenth consecutive quarter of revenue growth.
Read more →BNGOBionano Genomics Inc. Investors: Company Investigated by the Portnoy Law Firm
Bionano Genomics, Inc. is currently under investigation by the Portnoy Law Firm for potentially issuing false and misleading statements to investors. This follows a significant drop of over 20% in the company's stock after the announcement of a Series A Preferred share sold to Chairman David Barker, who gained substantial voting power. Investors are being encouraged to contact the law firm for legal advice regarding their rights and options for recovering losses. The law firm offers a complimentary case evaluation for aggrieved investors considering claims against the company.
Read more →BNGOBionano Announces Presentation of OGM Utility Across Cancer Genomics Research Applications at the American Association for Cancer Research (AACR) Annual Meeting
Bionano Genomics, Inc. announced its participation in the AACR Annual Meeting 2023, highlighting optical genome mapping (OGM) applications in cancer research. The event will feature presentations from industry experts discussing OGM's impact on cancer therapy and biomarker identification. Five scientific posters will showcase its utility in areas such as hematological malignancies and HRD analysis. The meeting aims to advance discussions on cancer science and foster collaboration among researchers.
Read more →BNGOBionano Announces Publication that Demonstrates OGM’s Utility for Resolving Complex Genetic Variation in Inherited Retinal Disease
Bionano Genomics has reported a significant advancement in genetic research through a study from Radboud University Medical Center, which demonstrates the use of optical genome mapping (OGM) in identifying structural variants linked to inherited retinal diseases. The study revealed a previously misidentified structural variant impacting the USH2A gene and underscored the importance of combining OGM with next-generation sequencing for enhanced genetic analyses. This research is particularly notable given that a substantial percentage of individuals with inherited retinal diseases remain genetically unexplained even after genome sequencing.
Read more →BNGOBionano Announces First Study Using OGM to Discover Structural Variants with Potential Relevance to Genetic Diagnosis of MRKH Syndrome, a Syndrome Impacting Reproductive System Development in 1 in 4,500 Females
Bionano Genomics, Inc. announced a groundbreaking study utilizing optical genome mapping (OGM) to identify structural variants associated with Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome, a condition affecting 1 in 4,500 females. The research involved samples from 87 MRKH patients and their 47 parents, leading to the detection of multiple rare structural variants that may illuminate the genetic causes of the syndrome. This study represents a significant advancement in understanding MRKH, possibly paving the way for better diagnosis and therapies.
Read more →BNGOBionano Laboratories Expands its Clinical Testing Menu with Launch of OGM-Based Laboratory Developed Tests (LDTs) for Prenatal and Postnatal Analysis
Bionano Laboratories has expanded its clinical testing menu with the introduction of two optical genome mapping-based laboratory developed tests (LDTs), the OGM-Dx Postnatal and Prenatal Whole Genome SV. These tests are designed to provide a thorough genome-wide analysis of structural variants, aiding in the diagnosis of various genetic conditions. The Postnatal test targets patients with diagnoses like autism spectrum disorder and developmental delays, while the Prenatal test is intended for assessing fetuses with suspected genetic anomalies. The company believes these innovations will enhance the diagnostic process for clinicians and their patients.
Read more →BNGOBionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Featuring OGM Utility Across a Broad Range of Research Applications
Bionano Genomics announced its participation in the ACMG Annual Meeting, featuring presentations on its optical genome mapping (OGM) technology. The event includes a scientific session where OGM's effectiveness in detecting structural variants and rare genetic disorders will be discussed. Bionano's CEO, Dr. Erik Holmlin, will present awards and emphasize the company's commitment to enhancing patient health through genomic solutions. The conference aims to foster collaboration among industry and academic professionals in genetic research.
Read more →BNGOBionano Genomics Reports Fourth Quarter and Full-Year 2022 Results and Provides Revenue Outlook for 2023
Bionano Genomics has released its financial results for the fourth quarter and full year of 2022, reporting a 30% year-on-year revenue increase for Q4 and a total of $27.8 million for the year, marking a 55% rise. They surpassed their revenue guidance due to increased adoption of their optical genome mapping technology, with significant growth in their installed systems. Additionally, they published positive validation studies for their technology's efficacy in genetic testing. The company projects a revenue increase for 2023, expecting to reach between $35 million and $38 million.
Read more →BNGOBionano Announces Two Publications from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing including the First Peer-Reviewed Publication on the Multi-Site Evaluation of OGM Against SOC
Bionano Genomics (BNGO) announced two publications detailing the results of clinical studies supporting optical genome mapping (OGM) as a standard of care in genetic testing. The peer-reviewed publication showed high concordance rates of OGM against various standard of care methods, demonstrating 99.5% concordance and an overall success rate of 98.8%. The preprint publication further evaluated OGM with an expanded sample size, showing a significant increase in reportable findings compared to standard methods, especially in cases of autism spectrum disorders. These findings suggest OGM's potential to enhance genetic testing accuracy and efficiency.
Read more →BNGOBionano to Report Fourth Quarter and Year End 2022 Financial Results and Host a Conference Call and Webcast March 9, 2023
Bionano Genomics, Inc. will hold a conference call and webcast on March 9, 2023, at 4:30 p.m. EST to report its financial results for the fourth quarter and the full year of 2022. The session aims to highlight recent corporate advancements alongside the financial disclosure. Registration is required for telephone participation, and a replay of the call will be made available on the company's investor relations website for at least 30 days.
Read more →BNGOBionano to Present at the 43rd Annual Cowen Healthcare Conference
Bionano Genomics, Inc. has announced that its leadership, including CEO Erik Holmlin, will present at the 43rd Annual Cowen Healthcare Conference. The presentation is set for March 6th, 2023, at 1:30 pm ET, and will provide a corporate overview of the company. A live webcast of the presentation will be available on Bionano's website, allowing wider access for stakeholders.
Read more →BNGOBionano Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies
Bionano Genomics, Inc. announced that its OEM partner, Beijing Genome Precision Technology (BGPT), has received NMPA approval for DNA isolation and labeling products tailored for in vitro diagnostics in hematologic malignancies. This approval allows BGPT to market Bionano's reagents to clinical laboratories in China. The registration is seen as a critical step in aiding the uptake of Bionano's optical genome mapping products within the Chinese market, expanding opportunities for both companies in the field of molecular diagnostics.
Read more →BNGOBionano Shares Overview of AGBT Pre-Conference Workshop Program Along with Details of Company’s Innovative Research Grant Opportunity
Bionano Genomics announced key developments during the AGBT 2023 pre-conference workshop, highlighting the potential of optical genome mapping (OGM) to replace traditional cytogenetic methods for structural variant detection. The company introduced its new research grant opportunity and shared advancements in collaboration with NVIDIA to enhance computational capabilities for OGM analysis. Presentations included case studies demonstrating OGM's effectiveness in identifying structural variations in rare diseases. Bionano also revealed upcoming product improvements aimed at increasing throughput and analysis efficiency for genome research.
Read more →BNGOBionano Strategy Day Highlighted the Company’s Strategic Initiatives and Growth Plans as well as OGM’s Competitive Value for Cell Bioprocessing, and Cancer and Genetic Disease Research
Bionano Genomics, Inc. (BNGO) recently held its first Strategy Day, focusing on its strategic initiatives and growth plans in the genomics market. The event showcased the company's commitment to optical genome mapping (OGM) applications in cancer, genetic diseases, and cell bioprocessing. With participation from notable researchers, discussions emphasized OGM's advantages over traditional methods and its potential in improving genomic analysis efficiency. Bionano also outlined its plans to drive OGM adoption and enhance product development through regulatory approvals and improved laboratory workflows.
Read more →BNGOBionano’s Symposium 2023 Featured Record Numbers of Presentations Demonstrating Applications of OGM Across Cell Bioprocessing and Constitutional Genetic Disease and Cancer Research
Bionano Genomics concluded its 2023 Symposium, showcasing a record 31 oral presentations and 69 scientific posters from top institutions. The event featured over 3,000 registrants and highlighted the effectiveness of optical genome mapping (OGM) for applications in genetic disease and cancer. Presenters emphasized OGM's ability to identify pathogenic variants, outperform traditional techniques, and improve laboratory workflows, particularly in terms of speed and cost-efficiency. The symposium underscored the growing global interest and engagement in genomic research utilizing OGM technology.
Read more →BNGOBionano Laboratories Expands its Clinical Testing Menu with Launch of its First OGM-Based Laboratory Developed Test (LDT) for Hematological Malignancies
Bionano Laboratories has introduced its first OGM-based laboratory developed test (LDT), OGM-Dx HemeOne, aimed at detecting structural variants in hematological malignancies. This new test enhances diagnostic and prognostic evaluation through optical genome mapping, offering an improved workflow compared to traditional cytogenetic methods. The test focuses on a range of hematological conditions and aims to assist oncologists in tailoring therapies for patients. This initiative follows the previously launched test for facioscapulohumeral muscular dystrophy, indicating Bionano's commitment to expanding its clinical capabilities.
Read more →BNGOBionano Announces Launch of Next-Generation Versions of its Reagent Kits and Chip Consumable, Along with Updates to its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow
Bionano Genomics (BNGO) has announced the launch of next-generation reagent kits and software enhancements for its optical genome mapping (OGM) workflow. The new Bionano Prep SP-G2 kit improves both DNA quality and throughput, while the DLS-G2 kit allows for faster turnaround times and greater reagent stability. Additionally, upgrades to the Saphyr Chip and instrument control software enhance sample processing capabilities. These innovations are designed to improve the efficiency and reliability of genome analysis in clinical and research settings.
Read more →BNGOBionano Genomics Announces the Final Speaker Lineup for Symposium 2023 with 30 OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Research Applications
Bionano Genomics has announced the 2023 Symposium, featuring 30 oral presentations on the applications of optical genome mapping (OGM) in genetic disease and cancer research across a four-day virtual event. A total of 27 customers will share their latest research findings, with sessions including live panel discussions and scientific posters. The symposium aims to foster collaboration within the OGM community and highlights significant improvements in workflow and data analysis since the last event in 2022. Registration for the Symposium is free and open to all interested parties.
Read more →BNGOBionano Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing
Bionano Genomics has published interim results from a clinical trial assessing Optical Genome Mapping (OGM) as a potential standard of care for prenatal genetic disease diagnosis. The study includes 200 samples from 123 unique prenatal cases and showcases OGM's impressive concordance of 100% with standard testing methods. This preliminary data suggests high technical performance and reproducibility of OGM. The ongoing clinical trial aims to further evaluate crucial endpoints including diagnostic yield and health economics, with a total of 414 subjects enrolled to date.
Read more →BNGOBionano to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIA
Bionano Genomics has announced a collaboration with NVIDIA to create an acceleration platform for its optical genome mapping (OGM) workflow. This partnership aims to improve data processing speeds while reducing associated costs and time required for secondary analysis. The new computation platform is projected to support analysis of multiple cancer workflows per week and will be integrated with Bionano's existing software for variant interpretation. A preview of this solution is scheduled to occur at the forthcoming Advances in Genome Biology and Technology meeting.
Read more →BNGOBionano Announces Publication from Institut Curie Showing Utility of OGM for Detection of HRD in Breast Cancer
Bionano Genomics announced a publication highlighting the effectiveness of optical genome mapping (OGM) in identifying homologous recombination deficiency (HRD) in breast cancer. The study showed that OGM outperformed traditional methods like whole genome sequencing (WGS) in sensitivity and cost-effectiveness. Researchers at Institut Curie analyzed breast carcinoma samples and found that OGM could capture more genomic events, including those missed by WGS. This advancement may allow for better patient access to PARP inhibitor treatments.
Read more →BNGOBionano Genomics Announces 2023 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Applications
Bionano Genomics has announced its 2023 Symposium scheduled for January 23-26, featuring four days of presentations on optical genome mapping (OGM) by 25 global researchers. The event aims to highlight advancements in genetic diseases, cancer research, and cell bioprocessing applications, with interactive panel discussions and scientific presentations. Despite the anticipated positive engagement, the company acknowledges potential challenges including competitive technologies and uncertainties regarding the widespread adoption of OGM techniques.
Read more →BNGOBionano Genomics to Host Strategy Day on February 2, 2023 in New York City
Bionano Genomics, Inc. is set to host its inaugural Strategy Day on February 2, 2023, at the Nasdaq MarketSite in New York City. The event will feature presentations from company leaders and panel discussions with experts in various research areas, including cancer and genetic disorders. A live webcast will enable wider audience participation, with an archive available for later viewing. This initiative demonstrates the company's commitment to transparency and stakeholder engagement.
Read more →BNGOBionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results - Preliminary Q4 revenue expected to be between $8.1 and $8.4 million; 29% to 33% increase over Q4 2021 - Reached installed base of 240 syste
Bionano Genomics reported preliminary financial highlights for Q4 and full-year 2022, indicating a revenue increase between $8.1 million and $8.4 million, up 29% to 33% compared to Q4 2021. The company has reached an installed base of 240 systems, marking a 46% year-over-year increase. All stated goals for 2022 were achieved or exceeded, reflecting strong business momentum. However, results remain preliminary and are subject to change following the completion of financial reporting processes.
Read more →BNGOBionano Genomics Announces American Society of Hematology (ASH) Annual Meeting Presentations Featuring OGM Utility Across Blood Cancer Research Applications
A scientific workshop will feature Dr. Rashmi Kanagal-Shamanna from the University of Texas MD Anderson Cancer Center delivering a presentation on the use of emerging technologies for prognostication and research into myeloid neoplasms Four scientific posters featuring results f
Read more →BNGO+ Investor Call and Webcast
+ Investor Call and Webcast November 29, 2022 Creating an End-to-End Solution for OGM & Transforming the Way the World Sees the Genome Legal Disclaimer This presentation contains forward-looking statements. Forward-looking statements describe future expectations, plans, result
Read more →BNGOBionano Genomics to Acquire Purigen Biosystems to Enable Further Simplified and Accelerated DNA Isolation for Optical Genome Mapping (OGM) and Address Difficult Sample Types in New Applications with Isotachophoresis (ITP
Bionano Genomics to Acquire Purigen Biosystems to Enable Further Simplified and Accelerated DNA Isolation for Optical Genome Mapping (OGM) and Address Difficult Sample Types in New Applications with Isotachophoresis (ITP) on the Ionic Purification System SAN DIEGO, November 28,
Read more →BNGOBionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionan
Read more →BNGOBionano Genomics Reports Third Quarter 2022 Financial Results and Highlights Recent Business Progress
– 55% year-over-year revenue growth in Q3 2022 – On track to achieve all 2022 ELEVATE! milestones – Strong balance sheet with $180.2 million in cash, cash equivalents, and available-for-sale securities at the end of Q3 2022 – Conference call today, November 3rd, 2022 at 4:
Read more →BNGOBionano Genomics Announces Extensive Lineup of Content at Association for Molecular Pathology (AMP) Annual Meeting Featuring OGM Utility Across Broad Range of Research Applications
Dr. Alka Chaubey, chief medical officer at Bionano, Dr. Nikhil Sahajpal, Greenwood Genetic Center, Dr. Rashmi Kanagal-Shamanna, MD Anderson Cancer Center, and Dr. Adam Smith, University Health Network will host a sponsored vendor presentation on studies that include multiple type
Read more →BNGOBionano Genomics to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast on November 3, 2022
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, November 3, 2022 at 4:30 p.m. Eastern Time to report financial results for the third quarter 2022 and to highlight recent c
Read more →BNGOBionano Genomics Announces Global User Event at Bionano Laboratories Before American Society of Human Genetics (ASHG) Annual Meeting
SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the company will host a “Meet the User” event today, October 24, 2022, at its new CLIA-certified Bionano Laboratories facility in advance of the American Society of Human Genetics (A
Read more →BNGOBionano Genomics Announces Presentation of OGM Utility Across Key Applications at American Society of Human Genetics (ASHG) Annual Meeting
Dr. Alka Chaubey, chief medical officer at Bionano, and Dr. Nikhil Sahajpal, fellow at Greenwood Genetic Center, will host a sponsored vendor presentation on a large clinical study utilizing optical genome mapping (OGM) for analysis of postnatal genetic disorders and the compleme
Read more →BNGOBionano Genomics Announces Six User Presentations of OGM Results in Cancer Genomics Research at the Spanish Society of Hematology (SEHH) 2022
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Spanish Society of Hematology (SEHH) 2022 Conference, with six scientific presentations from independent researchers covering a wide variety of the cancer g
Read more →BNGOBionano Laboratories to Provide Enhanced Genetic Counseling and Patient Care for Genetic Disorders with OptraHEALTH’s HealthFAX™
SAN DIEGO and SAN JOSE, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Bionano Laboratories and OptraHEALTH today announced their collaboration to utilize HealthFAX’s proprietary AI platform to enhance genetic counseling services and improve care for patients receiving diagnostic services th
Read more →BNGOBionano Genomics Announces Launch of CLIA-Certified Bionano Laboratories, and Expands its Clinical Testing Menu with Launch of First OGM-Based LDT for FSHD
SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano’s optical genome mapping (OGM) data services with the clinical testing services previously offered by L
Read more →BNGOBionano Genomics Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss
SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study utilizing OGM to detect cryptic balanced chromosomal rearrangements (BCRs) found in subjects who experienced recurrent pregnancy loss (RPL). Compared to
Read more →BNGOBionano Genomics Announces Publication of Study in MDS and AML Showing Utility for Refined Diagnostics and Prognostic Stratification
SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study evaluating the performance of OGM for detection of cytogenetic abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) samples.
Read more →BNGOBionano Genomics Announces Publication of Study Demonstrating Utility of OGM as Part of a Comprehensive Workflow for Quality Evaluation of Human Induced Pluripotent Stem Cells (iPSCs)
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study demonstrating the utility of optical genome mapping (OGM) as part of a workflow to evaluate the quality of hypoimmunogenic induced pluripotent stem cell
Read more →BNGOBionano Genomics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) announced today that company management will participate virtually at the H.C. Wainwright 24th Annual Global Annual Global Investment Conference, taking place September 12-14, 2022. A pre-recorded present
Read more →BNGOBionano Genomics Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to use optical genome mapping (OGM) to analyze the impact of chromothripsis (cth) and TP53 abnormalities on chronic lymphocytic leukemia (CLL) pat
Read more →BNGOBionano Genomics Announces First Publication Using OGM for Detection of Repeat Expansions in CANVAS and Adult-Onset Ataxia
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) in the analysis of repeat expansion disorders. Repeat expansion disorders are a class of d
Read more →BNGOBionano Genomics Reports Second Quarter 2022 Financial Results and Highlights Recent Business Progress
- 73% year-over-year revenue growth in Q2 2022 - Achieved all 1H 2022 ELEVATE! milestones - Strong balance sheet with $187.3 million in cash, cash equivalents, and available-for-sale securities at the end of Q2 2022 - Conference call today, August 4th, 2022 at 4:30 PM ET SAN
Read more →BNGOBionano Genomics Announces Publication of Landmark Research Study in Myelodysplastic Syndrome Showing OGM Data would Result in Revised Prognostic Risk Classification or Additional Actionable Variants in 28% of Study Participants
SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) for myelodysplastic syndrome (MDS) prognostication. In the peer-reviewed study, published
Read more →BNGOBionano Genomics to Report Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022
SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, August 4th, 2022 at 4:30 p.m. Eastern Time to report financial results for the second quarter 2022 and to highlight recent
Read more →BNGOBionano Genomics Announces its Participation at the Cancer Genomics Consortium 2022 Annual Meeting with 18 OGM Presentations Covering the Cancer Genomics Landscape
Dr. Alka Chaubey, chief medical officer at Bionano, will host a sponsored vendor panel presentation on the integration of optical genome mapping (OGM) and next generation sequencing (NGS) for clinical research in leukemia and lymphoma Four scientific platform presentations, one
Read more →BNGOBionano Genomics Announces Publication of a New Study Using OGM to Investigate Chromosome Instability during Culture of Induced Pluripotent Stem Cells
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced publication of a study using optical genome mapping (OGM) to investigate numerical and structural changes to two induced pluripotent stem cell (iPSC) lines, WTC-11 and Tuba1-GFP, d
Read more →BNGOBionano Genomics Announces Issuance of a U.S. Patent for Analysis of Small Nucleic Acid Fragments in Nanochannel Arrays
SAN DIEGO, June 29, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that the United States Patent and Trademark Office issued US Patent No.11,359,244 on June 14, 2022. The patent, titled “CHARACTERIZATION OF MOLECULES IN NANOFLUIDICS” claims method
Read more →BNGOBionano Genomics Announces Participation at the European Association for Cancer Research (EACR) Congress 2022 Featuring OGM Applications for Cancer Research
Bionano will exhibit its solutions relevant to cancer research: the Saphyr® system, NxClinical™ software and expert laboratory services A corporate satellite presentation by Alicia Bertolotti, Bionano, Dr. Sylvia Genovese, Bambino Gesù Children’s Hospital, and Dr. Juan Díaz-Mart
Read more →BNGOBionano Genomics Announces Participation at the European Society of Human Genetics Conference (ESHG) 2022 Featuring OGM Across a Broad Range of Clinical Research Applications and a Collaborative Product Development with Hamilton
The Long String VANTAGE for DNA isolation, a collaborative development between Bionano and Hamilton, and the world’s first automation solution for Ultra High Molecular Weight (UHMW) extraction used in optical genome mapping (OGM), will be on display at the conference A corporate
Read more →BNGOBionano Genomics Announces Publication of a New Study Using OGM to Investigate Inversions that May Lead to Genetic Disorders
SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data,
Read more →BNGOBionano Genomics Announces Canadian College of Medical Geneticists Presentation Featuring Applications of OGM for Genetic Research
SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data,
Read more →BNGOBionano Genomics Announces Participation at the Advances in Genome Biology and Technology (AGBT) General Meeting 2022
Dr. Alka Chaubey, chief medical officer of Bionano, will present a spotlight session titled “OGM + NGS for Transforming Genome Biology: The Future is Bright!” Bionano is a Bronze Sponsor at the conference, and will host customers, KOLs and VIPs from the genomics, cytogenetics, a
Read more →BNGOBionano Announces Glass Lewis Recommendation and Encourages Stockholders to Cast their Vote Ahead of June 9th Annual Meeting
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, t
Read more →BNGOBionano Genomics to Present at the 2022 H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today ann
Read more →BNGOBionano Genomics Announces Participation at the 2022 American Cytogenomics Conference (ACC) and a User Spotlight Event at Augusta University, a Center of Excellence for OGM
For the first time at this conference, Bionano will exhibit all of its cytogenetic research solutions: OGM solutions, NxClinical software and laboratory services In a dedicated OGM scientific session, six presentations will illustrate the application of Bionano’s OGM in prenatal
Read more →BNGOBionano Genomics Announces a Publication From the First Affiliated Hospital of Zhengzhou Highlighting the Utility of OGM
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, t
Read more →BNGOBionano Genomics Reports First Quarter 2022 Financial Results and Highlights Recent Business Progress
- 80% year-over-year revenue growth in Q1 2022 - Achieved all Q1 2022 ELEVATE! milestones - Strong balance sheet with $216.5 million in cash, cash equivalents, and available-for-sale securities at the end of Q1 2022 - Conference call today, May 5th, 2022 at 4:30 PM ET SAN DIE
Read more →BNGOBionano Genomics Announces Peer-Reviewed Publication of NeuroSCORE Model to Predict and Prioritize Human Genes Contributing to Neurodevelopmental Disease
SAN DIEGO, April 29, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data,
Read more →BNGOBionano Genomics to Report First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 5, 2022
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, May 5th, 2022 at 4:30 p.m. Eastern Time to report financial results for the first quarter 2022 and to highlight recent cor
Read more →BNGOBionano Genomics Announces Issuance of Two U.S. Patents for Novel Methods that Expand Patent Protection for Uses of Nanochannel Arrays in Genome Analysis
SAN DIEGO, April 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data,
Read more →BNGOBionano Genomics Announces Release of Version 6.2 of its NxClinical Software with Significant New Capabilities for Cancer Research Applications Including HRD Analysis
SAN DIEGO, April 07, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today a
Read more →BNGOBionano Genomics Announces Publication of a New Study Using OGM Combined with Multiple Analytical Methods Including Single-Cell Analysis as a Comprehensive Molecular Strategy to Characterize the Genomic Variation in B-cell Acute Lymphoblastic Leukemia
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today a
Read more →BNGOBionano Genomics Announces Participation at the American Association for Cancer Research Annual Meeting Spotlighting Optical Genome Mapping Applications and Enhanced NxClinical Capabilities for Cancer Research
Bionano will exhibit all of its solutions relevant to cancer research: OGM systems, NxClinical software and expert laboratory services Exhibitor Theater presentation will share the latest OGM research on comprehensive genomic structural variation and homologous recombination def
Read more →BNGOBionano Genomics Announces Speaker Lineup for 2022 China Symposium
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data,
Read more →BNGOBionano Genomics to Present at the 2022 Maxim Virtual Growth Conference
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, announc
Read more →BNGOBionano Genomics Announces its Participation at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting with Six Posters and All of its On-Market Solutions on Display
Bionano is back in-person at the ACMG annual meeting – this time as ONE COMPANY with MORE SOLUTIONS For the first time, Bionano will exhibit all of its products and solutions with its combined commercial teams together [in one location] Optical Genome Mapping Solutions, Testing
Read more →BNGOBionano Genomics Announces Publication of Comprehensive Validation of Optical Genome Mapping for Hematologic Neoplasms
Key findings from evaluation of 59 Heme Samples and 10 Controls: OGM detected 162/164 SVs detected by standard cytogenetics methods of karyotyping and FISH OGM detected chromosomal aberrations missed by karyotyping and FISH in 35 cases OGM Sensitivity: 98.7% OGM Specificity:
Read more →BNGOBionano Genomics to Present at the 32nd Annual Oppenheimer Healthcare Conference
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, a leading software solution for visualization, interpretation, and reporting of genomic data, announce
Read more →BNGOBionano Genomics Appoints Dr. Aleks Rajkovic to its Board of Directors
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data,
Read more →BNGOBionano Genomics to Present at the 42nd Annual Cowen Healthcare Conference
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClincial™, a leading software solution for visualization, interpretation and reporting of genomic data, announced
Read more →BNGOBionano Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022
Full-year 2021 revenue growth of 111% over 2020 Achieved publicly announced anticipated milestones for 2021 Strong balance sheet with $250.6 million in cash, cash equivalents, and available-for-sale securities as of YE 2021 Conference call today, March 1st, 2022 at 4:30 PM ET
Read more →BNGOBionano Genomics Announces Launch of Its Rare Undiagnosed Genetic Disease (RUGD) Strategic Initiative Aimed at the 350 Million People Globally Living with a Rare Disease
Rare diseases affect more than 350 million people globally It is estimated that 1 in 15 people globally are affected by a rare disease Estimates are that 25 million Americans and 30 million in Europe are living with a rare disease More than 7,000 rare diseases have been identi
Read more →BNGOBionano Genomics to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 1st, 2022
SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 1st, 2022 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2021 and t
Read more →BNGOBionano Genomics Announces Publication of Prospective Study Demonstrating Performance Improvements from OGM in the Analysis of AML and MDS Compared to Traditional Methods
SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today an
Read more →BNGOBionano Genomics Appoints Helene Klein as its First Ever Chief People Officer
SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today an
Read more →BNGOBionano Genomics Announces First Publication Demonstrating OGM as an Alternative to Karyotyping for Product of Conception Sample Analysis
SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today an
Read more →BNGOBionano Genomics to Present at the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, announce
Read more →BNGOBionano Genomics Announces UK Footprint Expansion with Adoption of its Saphyr System for Optical Genome Mapping in Two Genetic Laboratory Hubs within the United Kingdom’s National Health Service
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today a
Read more →BNGOBionano Genomics Announces Publication of the First Study to Combine OGM and NGS to Evaluate Myeloid Cancers
Whole genome analysis by OGM together with analysis using a 523-gene NGS panel can perform better and cost less than analysis with karyotyping, FISH, and a 54-gene NGS panel First study to publish results using NxClinical software for simultaneous visualization and interpretatio
Read more →BNGOBionano Genomics Announces Publication by International COVID-19 Host Genome Structural Variation Consortium Describing How OGM Identified Structural Variations as Predisposing Factors Associated with Severe COVID-19
SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today a
Read more →BNGOBionano Genomics Announces its Support for the AGMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program
SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today a
Read more →BNGOBionano Genomics Announces Record Daily Attendance for 2022 Symposium with 63% Increase Relative to Last Year
Average daily attendance of 565 in 2022 versus 346 in 2021 Over 4,000 registrants with attendees represented from 82 countries 31 oral presentations delivered across four consecutive days 37 scientific posters featuring OGM in the online exhibit hall On-demand presentations f
Read more →BNGOBionano Genomics Hosts Final Day of 2022 Symposium with Presentations Demonstrating the Combined Detection Power of OGM and NGS
SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, capped
Read more →BNGOBionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2021 Results - Preliminary Q4 revenue expected between $5.8 and $6.2 million; 45%-55% increase over Q4 2020 - Reached installed base of 164 systems: 69% i
Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2021 Results SAN DIEGO, January 12, 2022 (GLOBE NEWSWIRE) - Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr system and provider of NxClinical , the leading software
Read more →BNGOBionano Genomics Hosts Day 3 of 2022 Symposium with New Research Demonstrating Applications of OGM in Solid Tumor Analysis
SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, hosted
Read more →BNGOBionano Genomics Hosts Day 2 of 2022 Symposium with New Research Demonstrating How OGM Detects Known and Novel Variants in Hematologic Malignancies
SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, hosted
Read more →BNGOBionano Genomics Hosts Day 1 of 2022 Symposium with Six Presentations Highlighting the Superior Performance of OGM in Variant Detection for Constitutional Genetic Diseases
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, hosted
Read more →BNGOBionano Genomics Announces Publication of Interim Readout from the Consortium Conducting a Postnatal Clinical Trial Intended to Support Establishing Optical Genome Mapping as Part of Standard of Care in Genetic Disease Diagnosis
IRB-approved, multi-site, ongoing study evaluated 331 individual sample runs from 202 unique samples across 5 sites for interim measures of key endpoints: Concordance with standard of care (SOC) – 97.7% [214 out of 219 samples] Partially concordant with SOC – 2.3% [5 out of 219
Read more →BNGOBionano Genomics Announces the Final Speaker Lineup for 2022 Symposium
– 27 different customers representing North America and Europe – 31 oral presentations across four consecutive days – Topics span the application of OGM in genetic disease and cancer research – 45% of presentations are from North America and 55% are from Europe SAN DI
Read more →BNGOBionano Announces Prototype for its Next Single Molecule Imaging System for OGM
SAN DIEGO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced that
Read more →BNGOBionano Genomics Appoints Vince Wong to its Board of Directors
SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the
Read more →BNGOBionano Genomics Announces the Launch of Version 6.1 of BioDiscovery’s NxClinical Software for Genome Analysis with Expanded Capabilities for Visualization, Interpretation and Reporting of Next-Generation Sequencing Data in Genetic Diseases and Cancer
SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announced the launch of version 6.1 of
Read more →BNGOBionano Genomics Announces 2022 Symposium Featuring Four Consecutive Days of OGM Presentations and Live Panel Discussions Delivered by 25 Different Customers Across a Wide Range of Genetic Disease and Cancer Applications
SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announced its 2022 Symposium featuring
Read more →BNGOBionano Genomics Announces Publication of Study Evaluating Optical Genome Mapping for High Throughput Characterization of Cytogenomic Heterogeneity in MDS
SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announced the publication of a study o
Read more →BNGOBionano Genomics Appoints Dr. Keith Gligorich, Seasoned Leader in CLIA-Certified CAP-Accredited Lab Operations, as VP Operations for Bionano Laboratories
SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software for genomic data visualization, interpretation and reporting, today announced that it has appoi
Read more →BNGOBionano Genomics Announces Peer-Reviewed Publication from Johns Hopkins University Outlining a Stepwise Approach to the Adoption of Optical Genome Mapping for Cancer Analysis
SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announced the publication of a study b
Read more →BNGOBionano Genomics Announces Extensive Lineup of Content to be Presented at the Annual Meeting of the Association for Molecular Pathology Featuring Optical Genome Mapping Across a Broad Range of Clinical Research Applications
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) and provider of industry-leading data interpretation solutions for next-generation sequencing (NGS) and microarrays, today announced the lineup of content scheduled
Read more →BNGOBionano Genomics Announces the Appointment of Stephanie Hoyle as VP Corporate Marketing and Alex Helm as VP Strategic Product Marketing
SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced that two former Illumina executives, Stephanie Hoyle and
Read more →BNGOBionano Genomics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Progress
– Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics – Total revenue of $4.7 million, a 112% year-over-year total revenue inc
Read more →BNGOBionano Genomics Announces Major Updates to Its Solve™ and Access™ Data Solutions Adding Significant New Variant Detection, Analysis and Reporting Capabilities for Optical Genome Mapping on the Saphyr System
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced the release of Bionano Solve™ version 3.7 and Bionano Ac
Read more →BNGOBionano Genomics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that, in accordance with Nasdaq Listing Rule 5635(c)(4), the Compensation Committee of its Board of Directors granted the following non-qualified stock options pursuant to the compa
Read more →BNGOBionano Genomics to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 4, 2021
SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, November 4, 2021 at 4:30 p.m. Eastern Time to report financial results for the third quarter ended September 30, 20
Read more →BNGOBionano Genomics Announces American Society of Human Genetics Presentations Featuring Optical Genome Mapping for Genetic Disease and Cancer Research Applications
SAN DIEGO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced the American Society of Human Genetics (ASHG) conference
Read more →BNGOBionano Genomics to Acquire BioDiscovery, Furthering Bionano's Vision of Creating the Most Comprehensive Variant Analysis Platform in Genomics Designed to accelerate the adoption of optical genome mapping (OGM) with the
Bionano Genomics to Acquire BioDiscovery, Furthering Bionano's Vision of Creating the Most Comprehensive Variant Analysis Platform in Genomics SAN DIEGO, October 12, 2021 (GLOBE NEWSWIRE) - Bionano Genomics, Inc. (BNGO) today announced that it has entered into a definitive agre
Read more →BNGOBionano Genomics Expands Commercial Leadership Team to Accelerate Growth of Saphyr and Bolster Customer Support and Experience Globally
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced that the following individuals have joined the Company’s
Read more →BNGOBionano Genomics Announces ESHG Lineup Featuring 11 Customer Presentations of OGM Data Spanning Three Major Clinical Research Areas of Application from 10 Institutions and Six Countries
SAN DIEGO, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the European Society of Human Genetics (ESHG) conference lineup featuring 11 customer presentations of optical genome mapping (OGM) data spanning three major clinical areas of appli
Read more →BNGOBionano Genomics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Progress
226% year-over-year total revenue increase driven by growth in the Saphyr installed base All 2021 milestones on track Strong balance sheet with $333 million in cash as of June 30, 2021 Conference call today, Wednesday, August 4, at 4:30 pm ET SAN DIEGO, Aug. 04, 2021 (GLOBE N
Read more →BNGOBionano Genomics to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 4, 2021
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 4, 2021 at 4:30 p.m. Eastern Time to report financial results for the second quarter ended June 30, 2021 an
Read more →BNGOBionano Genomics Announces a Record Number of Optical Genome Mapping Presentations Scheduled to Appear at the Annual Cancer Genomics Consortium Meeting from August 1st - 4th, 2021
SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a record number of optical genome mapping (OGM) presentations scheduled to appear at the annual Cancer Genomics Consortium (CGC) meeting being held from August 1 - 4, 2021. Across t
Read more →BNGOBionano’s Optical Genome Mapping for Acute Lymphoblastic Leukemia Subjects at the University Hospitals Leuven, Belgium, Has Faster Turnaround Time, Higher Success Rates and Lower Cost per Sample Compared to Traditional Methods
SAN DIEGO, July 19, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announces a summary of the results obtained by the University Hospitals Leuven, Belgium with optical genome mapping (OGM) with Bionano’s Saphyr® system. An assay was developed for whole genome anal
Read more →BNGOBionano’s Optical Genome Mapping Reveals New Insights and Prognostic Capabilities Compared to Traditional Cytogenetics Techniques in Several Leukemia Clinical Research Studies Presented at the ECA
SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced optical genome mapping (OGM) reveals new insights and prognostic capabilities compared to traditional cytogenetics techniques in several leukemia clinical research studies presented
Read more →BNGOBionano’s Optical Genome Mapping Extensively Featured at the 2021 European Cytogenomics Conference as a Superior Solution for Genomic Analysis in Leukemia and Genetic Disease Compared to Traditional Techniques
SAN DIEGO, July 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that optical genome mapping (OGM) was extensively featured across a wide range of talks and posters at the 2021 European Cytogenomics Conference (ECA) as a superior solution for gen
Read more →BNGOBionano Genomics Announces Back-to-Back Publications in the American Journal of Human Genetics that Compare Optical Genome Mapping to Traditional Methods for Structural Variant Analysis in Inherited Genetic Disease and Hematological Malignancies
SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that two peer-reviewed studies from world renowned scientists and clinicians from prestigious institutions in Europe including Radboud University Medical Center, Cochin Hospital in
Read more →BNGOBionano Genomics Announces Significant Progress in China with WeHealth Shanghai’s Adoption of Bionano’s Saphyr System and the Demonstration by Various Institutions of Optical Genome Mapping in Reproductive Health and Genetics
SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced significant progress in China with the adoption of its Saphyr® System for optical genome mapping (OGM) by WeHealth Shanghai, a leading provider of genome analysis services in reproductive
Read more →BNGOBionano Genomics’ Chief Medical Officer Dr. Alka Chaubey and Cancer Genomics Consortium President Dr. Yassmine Akkari to Present on Optical Genome Mapping (OGM) at the 2021 International Conference of the Board of Genetic Counseling India
SAN DIEGO, July 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Chief Medical Officer Dr. Alka Chaubey and current President of the Cancer Genomics Consortium Dr. Yassmine Akkari will present at the 6th Annual International Conference of th
Read more →BNGOBionano Genomics to Present at the 2021 Ladenburg Thalmann Healthcare Conference
SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the 2021 Ladenburg Thalmann Healthcare Conference being held July 13-14, 2021. Erik Holmlin, PhD, Bionano’s Chief Executive Officer
Read more →BNGOBionano Genomics Added to Membership of US Small-Cap Russell 2000 Index
SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on Monday, June 28, 2021, as part of the 2021 Russell indexes reconstituti
Read more →BNGOBionano Genomics Appoints Richard Shippy, Former Affymetrix, Illumina and Cradle Executive, as its Chief Business Officer
SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Richard Shippy has joined the company as its Chief Business Officer. Richard was one of the transformational leaders at Affymetrix who brought microarrays into the clinic and p
Read more →BNGOBionano Genomics Appoints Jason Priar, Former GeneDx, Sema4 and PerkinElmer Genomics Sales Leader, as its Chief Commercial Officer
SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Jason Priar has joined the company as its Chief Commercial Officer. Jason is a seasoned sales leader with experience scaling businesses from early stage to hundreds of millions
Read more →BNGOBionano Genomics to Present at the 2021 Oppenheimer MedTech, Tools & Diagnostic Summit
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the Oppenheimer MedTech, Tools & Diagnostics Summit being held on May 26, 2021. The presentation will be available to view on the E
Read more →BNGOBionano Genomics Reports First Quarter 2021 Financial Results and Highlights Recent Business Progress
179% year-over-year revenue increase driven by record sales of consumables and growth in the Saphyr installed base All 2021 milestones on track Strong balance sheet with $362 million cash as of March 31, 2021 Conference call today, Thursday, May 13, at 4:30 pm ET SAN DIEGO, M
Read more →BNGOBionano Genomics to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 13, 2021
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, May 13, 2021 at 4:30 p.m. Eastern Time to report financial results for the first quarter ended March 31, 2021 and to
Read more →BNGOBionano Genomics Announces Issuance of US Patent for Targeted Labeling Strategy to Complement Whole Genome Analysis Using Optical Genome Mapping
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced that the United States Patent and Trademark Office will issue US Patent No. 10,995,364 today, May 4, 2021. The patent, titled “METHODS AND DEVICES FOR SINGLE-MOLECULE WHOLE GENOME ANALYSI
Read more →BNGOBionano Genomics Announces Publication of New Approach to Study DNA Replication Using Optical Genome Mapping With Saphyr, Potentially Supporting Development of Cancer Drugs Targeting Replication Pathways
SAN DIEGO, April 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today the publication of a study that analyzed the mechanisms of DNA replication, a fundamental process of cell growth implicated in cancer that was previously hard to study in human ge
Read more →BNGOBionano Genomics Announces Sites within the UK’s National Health System have Adopted its Saphyr System for Optical Genome Mapping
SAN DIEGO, April 21, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the adoption of its Saphyr system for optical genome mapping (OGM) by two large laboratories belonging to the National Health System (NHS) of the United Kingdom. King’s College Hospital
Read more →BNGOBionano Genomics Announces Pre-Clinical Evaluation of Optical Genome Mapping by the Foundation for Embryonic Competence
SAN DIEGO, April 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the launch of an IRB-approved preclinical evaluation study using optical genome mapping (OGM) by the Foundation for Embryonic Competence (FEC) based in Basking Ridge, NJ. FEC is a nonpro
Read more →BNGOBionano Genomics Announces Record Number of Presentations on Optical Genome Mapping and Structural Variation at the 2021 Annual Clinical Genetics Meeting of the ACMG
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced it largest presence to date at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics (ACMG), which is being held in a virtual format fr
Read more →BNGOBionano Genomics Announces Presentations on Optical Genome Mapping at the American Association for Cancer Research (AACR) Annual Meeting 2021
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that multiple studies on the detection of structural variants using Bionano’s optical genome mapping, including a Spotlight Presentation, will be presented at the American Associat
Read more →BNGOBionano Genomics Announces Continued Global Expansion in Adoption of its Saphyr System with Addition of Indalo Bio in South Africa, Bringing Advanced Genetic Analysis to Africa
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the adoption of the Saphyr system for optical genome mapping (OGM) by Indalo Bio (Pty) Ltd, an advanced molecular genetics laboratory based in Cape Town, South Africa, marking the first
Read more →BNGOBionano Genomics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates
-Solidified Financial Position Raising Approximately $335 Million in Q1 2021 -Executed on Commercial Offerings for Saphyr®, Driving Towards Global Adoption -Conference Call Today, March 23, 2021, at 4:30 pm EST SAN DIEGO, March 23, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, In
Read more →BNGOBionano Genomics to Present at Several Upcoming Investor Conferences
SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the following investor conferences: Oppenheimer 31st Annual Healthcare Conference, March 16-18, 2021 º Company management are s
Read more →BNGOBionano Genomics Presented at H.C. Wainwright Global Life Sciences Conference
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management presented virtually at the H.C. Wainwright Global Life Sciences Conference, which took place March 9-10, 2021. The presentation by Bionano CEO Dr. Erik Holm
Read more →BNGOBionano Genomics to Report Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call and Webcast on March 23rd, 2021
SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 23rd, 2021 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2020 and
Read more →BNGOBionano Customer Praxis Genomics Receives DEX Z-Codes from Palmetto for their Whole Genome Analysis LDT on Saphyr
SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Praxis Genomics, LLC received DEX Z-codes from Palmetto MolDX for its entire testing menu of laboratory developed tests (LDTs) based on Saphyr. The DEX Z-Code modifier is a un
Read more →BNGOBionano Genomics to Present at the Cowen 41st Annual Health Care Conference
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the Cowen 41st Annual Health Care Conference. Erik Holmlin, PhD, Bionano’s Chief Executive Officer, is scheduled to present on Thu
Read more →BNGOBionano to be Featured at AGBT 2021 with Presentations of Scientific Discoveries made with Saphyr in Psychiatric Disorders and Cancer
SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the 2021 Advances in Genome Biology and Technology (AGBT) meeting will feature presentations from scientists at leading research institutes and hospitals including Boston Chil
Read more →BNGOBionano’s Saphyr Data Prove Essential in Creating the Most Comprehensive, Ethnically Diverse Collection of Genome Variation Ever Completed
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication in Science of a study by the Human Genome Structural Variation Consortium (HGSVC) that used a combination of advanced sequencing and optical genome mapping (OGM) with Saph
Read more →BNGOBionano Publishes Method for Identifying Genes Likely to Cause Neurological Diseases Based on a Model Developed by Lineagen to Improve Interpretation of Variants of Unknown Significance
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study by its Lineagen team that describes the first genome-wide model to assess and score nearly all protein-coding genes based on their likelihood to cause central n
Read more →BNGOBionano Genomics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Erik Holmlin, PhD, Bionano’s Chief Executive Officer,
Read more →BNGOBionano Chief Medical Officer Presents Vision for Optical Genome Mapping as a First Line Clinical Tool for Cancer and Genetic Disease Testing at Festival of Genomics & Biodata
SAN DIEGO, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a presentation by Chief Medical Officer Dr. Alka Chaubey at The Festival of Genomics & Biodata where she presented evidence supporting her vision of Optical Genome Mapping (OGM) with Saph
Read more →BNGOBionano Significantly Reduces Analysis Cost and Time to Actionable Results with Update to its Cloud Compute
SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the release of version 1.2 of its Compute On Demand (COD) cloud compute solution which significantly reduces the cost and time to analyze structural variants (SVs) in a human genome. This
Read more →BNGOBionano Genomics Announces Closing of $230 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the closing of its previously announced underwritten public offering of 38,333,352 shares of its common stock, including 5,000,002 shares sold pursuant to the underwriters’ exercis
Read more →BNGOBionano Genomics Announces Pricing of $200 Million Underwritten Public Offering of Common Stock
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the pricing of its previously announced underwritten public offering of 33,333,350 shares of its common stock at a price to the public of $6.00 per share. The gross proceeds to Bio
Read more →BNGOBionano Genomics Announces Proposed Underwritten Public Offering of Common Stock
Bionano Genomics Announces Proposed Underwritten Public Offering of Common Stock SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it plans to offer and sell, subject to market and other conditions, shares of its common sto
Read more →BNGOBionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement for con
Read more →BNGOBionano Genomics Announces Closing of $101.8 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the closing of its previously announced underwritten public offering of 33,368,851 shares of its common stock, including 4,352,458 shares sold pursuant to the underwriters’ exercis
Read more →BNGOBionano Genomics Announces the Kick-Off of its Next-Generation Cytogenomics Symposium, The Largest Event Yet to Showcase Saphyr’s Utility in Genome Analysis for Genetic Disease and Cancer
SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the kick-off its 5-day Next-Generation Cytogenomics Symposium, which starts Monday January 11 and will feature 33 presentations by distinguished Saphyr users from leading hospitals and me
Read more →BNGOBionano Genomics Announces Pricing of $88.5 Million Underwritten Public Offering of Common Stock
SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the pricing of its previously announced underwritten public offering of 29,016,393 shares of its common stock at a price to the public of $3.05 per share. The gross proceeds to Bio
Read more →BNGOJanuary 2021R. Erik Holmlin, CEOChris Stewart, CFO Corporate Overview Legal DisclaimerThis presentation contains forward-looking statements. Forward-looking statements describe future expectations, plans, results or stra
January 2021R. Erik Holmlin, CEOChris Stewart, CFO Corporate Overview Legal DisclaimerThis presentation contains forward-looking statements. Forward-looking statements describe future expectations, plans, results or strategies and are generally preceded by terms such as "may,"
Read more →BNGOBionano Genomics Publishes Study on Autism Risk Genes After Detailed Analysis of The Genome of Professor Temple Grandin, Who Has Brought Awareness to Autism Spectrum Disorder Through Her Activism
SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today the publication in the Journal of Personalized Medicine by Lineagen, its CLIA certified diagnostic services subsidiary, of an analysis of Professor Temple Grandin’s genome in one o
Read more →BNGOBionano Genomics Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that Nasdaq has granted the Company an additional 180-day compliance period, or until June 28, 2021, to regain compliance with Nasdaq’s minimum $1.00 closing bid price per share re
Read more →BNGOBionano Customer Praxis Genomics Accredited by College of American Pathologists, Completing First LDT in US for Constitutional Genetic Disorders that Uses Whole Genome Analysis with Saphyr as Alternative to Chromosomal Microarray and Karyotyping
SAN DIEGO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that Praxis Genomics, LLC received accreditation from the College of American Pathologists (CAP), making it the first CAP-accredited, CLIA-certified diagnostic lab in the United St
Read more →BNGOBionano Genomics Achieves Key Milestone with Software Update for its Saphyr System that Increases Throughput to 96 Human Genomes Per Week and Adds Saphyr Assure for Monitoring System Health
Since its launch in 2017, Saphyr® throughput has increased by 1,400%, from a maximum of 384 human genomes per year to nearly 5,000 per year with the latest software release, representing the achievement of a goal of at least 12 genomes per day by the end of 2020 Generation 2 Sap
Read more →BNGOBionano’s Saphyr System Used to Characterize Virus Integration Into Human Genome
SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a paper in the Proceedings of the National Academy of Sciences (PNAS) that describes the detailed characterization of how and where the human herpesvirus 6 (HHV-6) inte
Read more →BNGOBionano Genomics Users Present the Saphyr System As a Novel Diagnostic Tool for Hematological Malignancies at ASH 2020
SAN DIEGO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its Saphyr System for optical genome mapping is being introduced as a novel diagnostic tool for heme malignancies by Dr. Rashmi Kanagal-Shamanna of the MD Anderson Cancer Center at t
Read more →BNGOBionano Genomics and its Users Present the Saphyr System for Optical Genome Mapping and Various Advancements in Clinical Variant Detection at AMP 2020
SAN DIEGO, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the performance and application of its Saphyr system for optical genome mapping are being showcased at the Annual Meeting of the Association for Molecular Pathology (AMP), being held
Read more →BNGOBionano Genomics Reports Third Quarter 2020 Financial Results and Provides Business Update
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for
Read more →BNGOBionano Genomics Releases Major Update to Its Suite of Software Tools That Simplifies Clinical Analysis, Reduces Time to Actionable Results and Makes Adoption by Clinical Labs Easier
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) announces the most significant update to its suite of software tools for data analysis since the launch of Saphyr in 2017. This version of Bionano Access contains over 100 new features and revisions desi
Read more →BNGOBionano Genomics' Saphyr System Shown to be Indispensable for the Analysis of Certain Genetic Disease Causing Variants
SAN DIEGO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that a study led by scientists and clinicians from the Institute for Human Genetics at the UCSF School of Medicine and the Department of Pediatrics at the University of Colorado School of
Read more →BNGOBionano Genomics to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 12
Bionano Genomics to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 12 SAN DIEGO, October 15, 2020 - Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences company that develops and markets Saphyr , a platform for ultra-sensitive
Read more →BNGOBionano's Saphyr Plays Essential Role in Identifying Three Previously Unknown Genetic Mutation Types in Cancer in Study from Weill Cornell
SAN DIEGO, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that its Saphyr system played a key role in a research study by Marcin Imielinski, M.D., Ph.D., Assistant Professor of Pathology and Laboratory Medicine at Weill Cornell Medical Sch
Read more →BNGOBionano Genomics Announces Positive Outcome of Its Special Stockholder Meeting
SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that its stockholders have voted in favor of the company’s proposal to increase the number of its authorized shares of common stock. “We appreciate the support of our stockholders
Read more →BNGOBionano Genomics Announces Continued Expansion of Global Business with Adoption of Saphyr for Next-Generation Cytogenomics in Eastern Europe and Australia
SAN DIEGO, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that its Saphyr system has been adopted through reagent-rental agreements by two renowned institutions in Australia and Slovenia: the Royal North Shore Hospital in Northern Sydney,
Read more →BNGOBionano to Present at the September 2020 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Erik Holmlin, Ph.D., CEO of Bionano, will present a company overview and be available for virtual one-on-one meetings with investors at the Oppenheimer Fall Healthcare Life Sc
Read more →BNGOBionano Data Provides Understanding of Repeat Expansion Disorders Causing Muscular Dystrophy and ALS
SAN DIEGO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that teams from the Mayo Clinic and from the University of Florida have separately released results generated with Saphyr relating to Amyotrophic Lateral Sclerosis (ALS) and Myoton
Read more →BNGOBionano Genomics Continues to See Expansion in the Adoption of Saphyr for Digital Cytogenetics at Leading Medical Institutions
SAN DIEGO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that its Saphyr system has been adopted through reagent-rentals by four additional institutions in Europe: the Department of Human Genetics, Ruhr University Bochum and the Clinic f
Read more →BNGOBionano Genomics Expands Its Diagnostic Testing Menu with Launch of Lineagen’s EpiPanelDx PLUS Gene Panel Test that Identifies Genetic Conditions Related to Epilepsy
EpiPanelDx PLUS adds to Lineagen’s expanding menu of diagnostic tests for children with developmental disorders and provides an offering designed specifically for patients that have experienced seizures or other epilepsy-related symptoms SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE
Read more →BNGOBionano Genomics Announces Continued Expansion of European Business With Adoption of Saphyr at Three of Europe’s Largest Pediatric Hospitals in Spain, Italy and France
SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that its Saphyr system has been adopted through reagent-rental agreements by three renowned institutions in Spain, Italy and France: Niño Jesús University Children's Hospital in Ma
Read more →BNGOBionano Genomics Data is a Key to Understanding Cancer Genome Structures That Make Tumors Grow Aggressively
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today a study published in the journal Nature Communications used its genome imaging technology to increase understanding of the genome structures that make tumors like glioblastoma mult
Read more →BNGOBionano Genomics Announces Adjournment of Special Meeting of Stockholders to September 29, 2020
SAN DIEGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it has adjourned its Special Meeting of Stockholders held on August 31, 2020 to allow additional time to secure sufficient votes for its proposal to increase the number of its
Read more →BNGOBionano Genomics Emphasizes the Importance of Supporting the Proxy Proposal to Increase its Authorized Shares
SAN DIEGO, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that on August 26, 2020, it commenced mailing an open letter to stockholders in support of its proposal to increase authorized shares, a copy of which is included at the end of this
Read more →BNGOBionano Genomics Appoints Tech Executive Christopher Stewart as its Chief Financial Officer to Help Manage, Grow and Expand Bionano's Global Business Chris Stewart joins Bionano from Tesla where he headed up the ultracap
Bionano Genomics Appoints Tech Executive Christopher Stewart as its Chief Financial Officer to Help Manage, Grow and Expand Bionano's Global Business Chris Stewart joins Bionano from Tesla where he headed up the ultracapacitor business unit. Over his career, he has served in a
Read more →BNGOBionano Genomics Acquires Diagnostics Services Provider Lineagen, Inc. to Accelerate Clinical Adoption of Saphyr for Digital Cytogenetics Lineagen is a provider of proprietary molecular diagnostics services for individua
Bionano Genomics Acquires Diagnostics Services Provider Lineagen, Inc. to Accelerate Clinical Adoption of Saphyr for Digital Cytogenetics SAN DIEGO, August 24, 2020 -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has acquired Lineagen Inc., a Salt Lake City, Ut
Read more →BNGOBionano Saphyr Services Offered in CLIA Certified Lab Expands Bionano Genomics’ Clinical Applications
Praxis Genomics is first CLIA Lab to become a Bionano Certified Service Provider, will use Saphyr in its goal to help end diagnostic odyssey for patients. SAN DIEGO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that Praxis Genomics has
Read more →BNGOBionano Genomics Appoints Industry Leading Cytogeneticist Dr. Alka Chaubey as the Company’s First Chief Medical Officer to Help Lead the Conversion of Cytogenetics to Digital Cytogenetics with Saphyr
SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Dr. Alka Chaubey, PhD, FACMG, will join Bionano as its first Chief Medical Officer, effective August 31, 2020. Dr. Chaubey is well known throughout the molecular diagnostics an
Read more →BNGOBionano Genomics Announces “At-The-Market” Equity Program
SAN DIEGO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it has filed a prospectus with the Securities and Exchange Commission (“SEC”), under which it may offer and sell shares of its common stock (the “Shares”) having an aggregate o
Read more →BNGOBionano Genomics Reports Second Quarter 2020 Financial Results and Provides Business Update
SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its f
Read more →BNGOBionano Featured at Cancer Genomics Consortium Annual Meeting with Multiple Data Readouts that Further Validate Saphyr in the Field of Cytogenetics and Lay Groundwork for a Novel LDT in Cancer
In a new study at Children’s Hospital of Los Angeles evaluating children with B-ALL, the most common type of cancer in children, researchers using Saphyr discovered an oncogenic variation that they believe may cause the disease in some patients and could be prognostic of disease
Read more →BNGOBionano Genomics to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 13
SAN DIEGO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that
Read more →BNGOBionano Genome Imaging Provides Essential Scaffolding Results in High Profile Bat Genome Study
SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that a study published in the journal Nature (Jebb, D., Huang, Z., Pippel, M. et al. Six reference-quality genomes reveal evolution of bat adaptations. Nature 583, 578–584 (2020)) u
Read more →BNGOBionano Genome Imaging Identifies the Most Common Structural Variations Between Individuals with DiGeorge Syndrome
Nature paper documents largest study of a single genetic disorder using Bionano genome imaging technology to date. Only Bionano’s Saphyr system was capable of resolving this extremely complex genome structure. SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (
Read more →BNGOBionano Genomics Data is Essential Part of the First Ever Complete Assembly of a Human X-Chromosome
SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that the first ever complete assembly of a human chromosome utilized its genome imaging technology to assemble the genome correctly and verify the accuracy. In a publication in Nat
Read more →BNGOBionano Genomics Solidifies its Entry into Solid Tumor Analysis with Launch of New Kit and Protocol that Significantly Simplify Tissue and Solid Tumor Analysis
SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has launched the new Bionano PrepTM SP Tissue and Tumor Kit, a DNA isolation kit developed expressly for analysis of tumors and tissue with Bionano’s Saphyr system. The kit
Read more →BNGOBionano Genomics Reports First Quarter 2020 Financial Results and Provides Business Update
SAN DIEGO, June 18, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its f
Read more →BNGOBionano Announces Amendment to Proxy Statement for Annual Meeting of Stockholders
SAN DIEGO, June 18, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that on June 17, 2020 it filed an amendment to its Proxy Statement for its 2020 Annual Meeting of Stockholders in order to amend and supplement Proposal 1 in the Proxy Statement. Pu
Read more →BNGOBionano Genomics to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on June 18
SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that
Read more →BNGOBionano Genomics Announces Issuance of US Patent for Combined Nanochannel-Nanopore Device
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the United States Patent and Trademark Office will issue US Patent No. 10,676,352 on June 9th, 2020. The patent, titled “NANONOZZLE DEVICE ARRAYS: THEIR PREPARATION AND USE FOR
Read more →BNGOBionano to Participate in Maxim Group’s Covid-19 Virtual Conference Series: The Role of Cell Therapy and Clarity on Testing
SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that Erik Holmlin, Ph.D., CEO of Bionano, will participate on a panel entitled: “Testing and Susceptibility – Clearing the Air,” during the virtual conference “The Role of Cell Thera
Read more →BNGOBionano Genomics to Report First Quarter 2020 Financial Results on
Bionano Genomics to Report First Quarter 2020 Financial Results on June 18, 2020 SAN DIEGO, May 14, 2020 - Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr , a platform for ultra-sensitive and ultra-specific structur
Read more →BNGOBionano Genomics Adds Healthcare and Genomics Industry Experts with Experience in Commercialization and Reimbursement to Its Board of Directors
SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced the appointment of Hannah Mamuszka and Yvonne Linney, PhD, to its board of directors. Junfeng Wang, who originally joined the company’s board as a representative of Legend Capital,
Read more →BNGOBIONANO GENOMICS ANNOUNCES PRICING OF $18 MILLION UNDERWRITTEN PUBLIC OFFERING
SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (NASDAQ: BNGO), a genome analysis company that provides tools and services based on its Saphyr® system to scientists and clinicians conducting genetic research and patient testing, today announced the pricing of
Read more →BNGOBionano Genomics to Support Largest Study to Date on COVID-19 Disease Susceptibility
SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today the launch of the largest study to date aiming to identify genomic variants and novel active substances that influence resistance or sensitivity to the SARS-CoV2 virus, or COVID-1
Read more →BNGOBionano Genomics Will Be Used in Research Identifying Gene Variants that Contribute to Coronavirus Disease Susceptibility
SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics announced the launch of a global network of studies aiming to identify genomic variants that influence COVID-19 disease resistance, sensitivity, disease progression and drug response. The first study will focus on the
Read more →BNGOBionano Genomics Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update
SAN DIEGO, March 05, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its
Read more →BNGOBionano Genomics to Report Fourth Quarter and Year End 2019 Financial Results and Host a Conference Call and Webcast on March 5
SAN DIEGO, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that
Read more →BNGOBionano Genomics Releases Saphyr Updates for Industry-Leading Data Yields that Enable Analysis of Complex Cancer Samples at Unprecedented Depths
SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) today announced updates to the Saphyr® System designed to increase the speed of data collection, simplify sample preparation for solid tumors and animal tissue and significantly improve the total data yi
Read more →BNGOBionano Genomics Data Drives Scientific Discoveries in Solid Tumors and Leukemias, To Be Presented at the 2020 AGBT Conference
SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, announced today that
Read more →BNGOBionano Genome Imaging Concordant with Traditional Cytogenetics in Landmark Leukemia Study
SAN DIEGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that a team led by Dr. Alexander Hoischen from Radboud University Medical Center (RUMC) in the Netherlands reported the results of a successful validation study comparing the perfor
Read more →BNGOBionano Genomics’ Saphyr System is Adopted by GeneDx for the Clinical Detection of Genetic Variants in Muscular Dystrophies, Developmental and Reproductive Disorders
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets the Saphyr® System, a genome imaging platform for ultra-sensitive and ultra-specific genome-wide structural variation detection, t
Read more →BNGOBionano Genomics Reports Third Quarter 2019 Financial Results and Provides Business Update
SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its f
Read more →BNGOBionano Genomics to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 7
SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that
Read more →BNGOBionano Genomics Announces Pricing of $18 Million Underwritten Public Offering
SAN DIEGO, Oct. 21, 2019 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced the p
Read more →BNGOBionano Genomics Announces Adoption of Its Saphyr System by Clinical Cytogenetics Groups in Academia and Industry to Replace Traditional Methods for Clinical Testing
SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets the Saphyr® system, a genome imaging platform for ultra-sensitive and ultra-specific genome-wide structural variation detection, t
Read more →BNGOBionano Genomics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
SAN DIEGO, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced tha
Read more →BNGOBionano Genomics Releases Users’ Video Presentations of Preliminary Data Affirming Saphyr's Potential to Replace Traditional Cytogenetics Methods in Certain Blood Cancers
SAN DIEGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced the
Read more →BNGOBionano Genomics Reports Second Quarter 2019 Financial Results and Provides Business Update
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its f
Read more →BNGOBionano Genomics to Report Second Quarter 2019 Financial Results and Host a Conference Call and Webcast on August 8
SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that
Read more →BNGOBionano Genomics Appoints Kristiina Vuori, MD, PhD, to its Board of Directors
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced the
Read more →BNGOBionano Genomics Reports First Quarter 2019 Financial Results and Provides Business Update
SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported financ
Read more →BNGOBionano Genomics to Report First Quarter 2019 Financial Results and Host a Conference Call and Webcast on May 9
SAN DIEGO, May 03, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that i
Read more →BNGOBionano Genomics to Present at the 31st Annual ROTH Conference
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that
Read more →BNGOBionano Genomics to Report Fourth Quarter and Fiscal Year 2018 Financial Results and Host a Conference Call and Webcast on March 14, 2019
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that
Read more →BNGOBionano Genomics to Present at the Cowen and Company 39th Annual Health Care Conference
SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that
Read more →BNGOBionano Genomics Launches New Capabilities of the Saphyr System to Significantly Increase Its Cost Effectiveness, Speed and Ease of Use for Whole Human Genome Structural Variation Analysis and Digital Cytogenetics
SAN DIEGO, March 01, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, announced at the 201
Read more →BNGOBionano Genomics’ Saphyr System Used for Highly Accurate Detection of the Genetic Disorder FSHD as an Alternative to Southern Blot
SAN DIEGO, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, announces the releas
Read more →BNGOBionano Genomics Releases Operating Results for Third Quarter 2018 Completed recent IPO raising $23.7 million in gross proceeds 23% increase in product revenue for the first nine months of 2018
Bionano Genomics Releases Operating Results for Third Quarter 2018 Completed recent IPO raising $23.7 million in gross proceeds 23% increase in product revenue for the first nine months of 2018 SAN DIEGO, Nov. 7, 2018 (GLOBE NEWSWIRE) - Bionano Genomics, Inc. (NASDAQ: BNGO), a
Read more →BNGOBionano Genomics to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
Call Scheduled for Wednesday, November 7th @ 4:30pm Eastern Time SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific struct
Read more →BNGOBionano and Genoox Launch Integrated Platform for Identification of Structural Variants in DNA
SAN DIEGO, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, and Genoox, the healt
Read more →BNGOBionano Genomics’ Structural Variation Results Presented at ASHG 2018 Provide Insights in Cancer and Genetic Disease
SAN DIEGO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, announces a series of
Read more →BNGOBionano Genomics Announces the Separate Trading of Its Common Stock and Warrants
SAN DIEGO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, announced today that
Read more →BNGOBionano Genomics Announces Pricing of Initial Public Offering
SAN DIEGO, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (“Bionano”), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced the pric
Read more →BNGOBionano Genomics Announces Global Launch of its New Direct Labeling Chemistry for Genome Mapping and Structural Variation Analysis
Direct Labeling chemistry provides chromosome arm length maps and improves SV detection resolution down to 500 bp for as little as $500 per genome To be showcased at the AGBT General Meeting this week SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, the genome ma
Read more →BNGOBionano Genomics’ Early-Access Customers to Present Groundbreaking Genome Assembly Data Using Bionano’s New Labeling Technology at PAG XXVI Conference
SAN DIEGO, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, the genome mapping company, today announced multiple oral and poster presentations featuring genome assembly data generated with its upcoming new labeling technology, to be presented at the International Plant & Anima
Read more →BNGOBionano Genome Mapping Found to Be Superior to Existing Clinical Tests for the Identification of Pathogenic Structural Variants in Duchenne Muscular Dystrophy
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- In a publication in Genome Medicine, a team of researchers from Children’s National Health Center (CNHC) and the University of California, Los Angeles (UCLA) led by Dr. Eric Vilain report the first molecular diagnoses of patients with
Read more →BNGOBionano Genomics’ Structural Variation Data Featured In Many Scientific Presentations at the ASHG 2017 Annual Meeting
SAN DIEGO, Oct. 09, 2017 (GLOBE NEWSWIRE) -- Bionano Genomics, the structural variation company, announces a series of presentations at the upcoming American Society of Human Genetics (ASHG) Annual Meeting, October 17 to 21 in Orlando, Florida. Bionano will present Saphyr™, its m
Read more →BNGOBionano Genomics Announces Inversion Detection Algorithms With Unmatched Sensitivity
SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Bionano Genomics®, Inc., a company focused on genome structure analysis, today released updated algorithms, analysis tools and visualization software enabling industry leading performance for the genome wide detection of inversions.
Read more →BNGOBionano Genomics Announces Immediate Availability of New Suite of Genomic Analysis Tools
SAN DIEGO, April 04, 2017 (GLOBE NEWSWIRE) -- Bionano Genomics®, Inc., a company focused on genome structure analysis, today announced the immediate availability of its entirely new suite of tools for genome assembly, structural variation (SV) detection, and visualization of the
Read more →BNGOBionano Genomics Announces Global Launch of Saphyr™, its Newest and Most Advanced System for Genome Mapping and Structural Variation Analysis
Saphyr brings comprehensive structural variation detection with industry-leading sensitivity, specificity at high speed and high throughput To be showcased at the AGBT General Meeting this week SAN DIEGO, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Bionano Genomics, a company focused on
Read more →BNGOBionano Genomics Announces Multiple Presentations Demonstrating How Its Next-Generation Mapping Accelerates Pace of Human Disease Research at AGBT General Meeting 2017
SAN DIEGO, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Bionano Genomics, the leader in physical genome mapping, today announced that multiple presentations describing the application of its next-generation mapping (NGM) to clinically relevant human genome research will be presented at the
Read more →BNGOBionano Genomics Reports Industry-Leading Detection of Structural Variants with More than 90% Sensitivity
New Bionano Solve 3.0 assembly and analysis software to be released this quarter SAN DIEGO, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Bionano Genomics, the leader in physical genome mapping, today released the first comprehensive dataset outlining the performance of large structural var
Read more →BNGOBionano Genomics Highlights Five Studies at PAG XXV Demonstrating How Next-Generation Mapping Improves Assembly of and Structural Variation Detection in Complex Plant and Animal Genomes
SAN DIEGO, Jan. 16, 2017 (GLOBE NEWSWIRE) -- Bionano Genomics, the leader in physical genome mapping, highlighted results from five studies demonstrating how using next-generation mapping (NGM) reveals true genome structure as well as improves the assembly of complex plant and an
Read more →BNGOBionano Genomics Announces 36 Posters and Workshops Supporting Next-Generation Mapping to be presented at PAG XXV Conference
SAN DIEGO, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Bionano Genomics, the leader in physical genome mapping, today announced 36 posters and workshops demonstrating how using next-generation mapping (NGM) to reveal true genome structure uniquely enables significant advances in plant and
Read more →BNGOBioNano’s Next-Generation Mapping (NGM) Used to Reveal the Genome Structure of the Korean Genome
NGM plays important role in revealing full range of structural variations across human genomes Highlights importance of population-specific references to advance clinically-relevant precision medicine SAN DIEGO, Oct. 14, 2016 (GLOBE NEWSWIRE) -- BioNano Genomics, Inc., the lead
Read more →BNGOBioNano Genomics to Present Results Supporting Next-Generation Mapping in Human Genome Research at ASHG 2016 Annual Meeting
SAN DIEGO, Oct. 10, 2016 (GLOBE NEWSWIRE) -- BioNano Genomics, Inc., the leader in physical genome mapping, today announced that it will present four posters, host a workshop and highlight industry research through oral presentations all supporting the utility of next-generation
Read more →BNGOBioNano Elects David Barker, Ph.D., Former Chief Scientific Officer of Illumina, as Chairman of the Board
SAN DIEGO, Sept. 08, 2016 (GLOBE NEWSWIRE) -- BioNano Genomics, the leader in physical genome mapping, today announced that it has elected David Barker, Ph.D., former Chief Scientific Officer of Illumina, as Chairman of the Board. BioNano has further strengthened its executive ma
Read more →BNGOBioNano Genomics and Berry Genomics to Co-Develop Next-Generation Mapping System for CFDA-Approved Clinical Use in China
SAN DIEGO and BEIJING, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Berry Genomics Co., Ltd. announced today that it has chosen BioNano Genomics’ Irys® system for next-generation mapping (NGM) as the platform on which Berry will seek Chinese Food and Drug Administration (CFDA) regulatory ap
Read more →BNGOBioNano Releases Updated Irys Data Solutions for Improved Structural Variation Analysis in Human Samples
Irys® currently the only platform enabling translational research through large SV discovery Company to discuss new solution at Festival of Genomics in Boston this week SAN DIEGO, June 27, 2016 (GLOBE NEWSWIRE) -- BioNano Genomics, the leader in physical genome mapping, today a
Read more →BNGOBioNano Announces Adoption of the Popular VCF Format
SAN DIEGO, June 07, 2016 (GLOBE NEWSWIRE) -- BioNano Genomics, the leader in physical genome mapping, today announced two major advances in the integration of data from the Irys® System into the industry’s standard formats and visualization tools. The first advance is the adoptio
Read more →BNGOBioNano Next-Generation Mapping Yields Superior Genomic Assemblies with Greater Contiguity
SAN DIEGO, May 10, 2016 (GLOBE NEWSWIRE) -- BioNano Genomics, the leader in physical genome mapping, today announced publication of another study describing application of its next-generation mapping (NGM) technology as the critical component in achieving high-quality de novo hum
Read more →BNGOBioNano Genomics Launches Enhanced Genome Mapping Coverage Features with New Software Tools
Availability of a new enzyme from New England BioLabs Inc. further expands BioNano genome mapping capabilities SAN DIEGO, May 04, 2016 (GLOBE NEWSWIRE) -- BioNano Genomics, the leader in physical genome mapping, today announced updates regarding expansions of its product offerin
Read more →BNGOBioNano Genomics Announces 32 Posters and Workshops Supporting Next-Generation Mapping to be Presented at PAG XXIV Conference
SAN DIEGO, Jan. 07, 2016 (GLOBE NEWSWIRE) -- BioNano Genomics, the leader in physical genome mapping, today announced that 32 posters and workshops supporting the utility of its next-generation mapping (NGM) Irys® System in plant and animal genome research will be presented at th
Read more →BNGOBioNano Genomics Highlights Study Using Next-Generation Mapping for 7-Fold Improvement in Structural Variation Detection Versus NGS
SAN DIEGO, Jan. 05, 2016 (GLOBE NEWSWIRE) -- BioNano Genomics, the leader in physical genome mapping, today announced results from a study demonstrating the enhanced ability of single-molecule next-generation mapping (NGM) using BioNano’s Irys® System to detect and reveal genome-
Read more →BNGOBioNano Genomics Highlights Results from Next-Generation Mapping Study of Large Yellow Croaker Published in BMC Genomics
SAN DIEGO, Oct. 15, 2015 (GLOBE NEWSWIRE) -- BioNano Genomics, Inc., the leader in physical genome mapping, today announced results from a study validating the ability of next-generation mapping to construct the first whole-genome map for large yellow croaker. The large yellow cr
Read more →BNGOBioNano Genomics Announces Research Collaboration With UCLA
SAN DIEGO, Oct. 8, 2015 (GLOBE NEWSWIRE) -- BioNano Genomics, the leader in physical genome mapping, today announced that the Company has entered into a research collaboration agreement with the University of California, Los Angeles (UCLA). The research is intended to study the r
Read more →BNGOBioNano Genomics Data Demonstrate Next-Generation Mapping as New Standard for Accurate and Complete Genome Assembly
SAN DIEGO, Oct. 6, 2015 (GLOBE NEWSWIRE) -- BioNano Genomics, the leader in physical genome mapping, today announced findings supporting its next-generation mapping (NGM) platform, the Irys System, to be presented in five poster presentations at the 2015 American Society of Human
Read more →BNGOBioNano Genomics to Present Five Posters Supporting Next Generation Mapping at ASHG 2015 Annual Meeting
SAN DIEGO, Sept. 28, 2015 (GLOBE NEWSWIRE) -- BioNano Genomics, Inc., the leader in physical genome mapping, today announced that it will present five posters supporting the utility of its Irys System in human genome research at the upcoming 2015 American Society of Human Genetic
Read more →BNGOBioNano Genomics Sees Continued Adoption of Their Irys System in Asia-Pacific
SAN DIEGO and BEIJING, July 22, 2015 (GLOBE NEWSWIRE) -- BioNano Genomics announced today the purchase of an Irys System by Biomarker Technologies Corporation located in Beijing, China. Biomarker selected BioNano's platform to enable comprehensive exploration of genomics structur
Read more →Competitive Position
How BNGO ranks across every disease it competes inCompetitive Position is a premium feature
See how BNGO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial